annual reportkey figure group sale operate free cash flow million chf cer million chf cer core operating profit ifrs net income million chf cer million chf cer core earning share dividend chf cer chf total shareholder return value chf invest period end dec feb apr jun aug oct dec roche gs price roche b price peer set index sustainable company patient clinical trial patient treat employee global leader innovation biotech oncology vitro diagnostic hospital market cer constant exchange rate average fullyear price translate constant chf exchange rate ifrs international financial reporting standard usd eur jpy gbp propose board director roche selling product fulltime equivalentsroche annual report make innovation accessiblekey event roche group roche deliver strong john c reed head performance pharma research increase ifrs early development net income agm prior join roche board director ceo sanfordburnham propose increase medical research institute dividend chf california united states th increase year roche sign agreement roche announce plan partner multi invest million swiss franc tude area include immu global biologic medi notherapy cancer anti cine manufacturing biotic multiresistant network meet increase bacteria technology demand new diagnostic test pharmaceutical kadcyla fda grant perjeta antibodydrug conjugate accelerate approval approve united states use surgery european union people herpositive treatment people earlystage breast cancer herpositive metastatic breast cancer gazyva receive approval roche discontinue treatment people development activity previously untreated aleglitazar medicine chronic lymphocytic leukemia aim treating diabete relate heart condition phase iii trial reviewcorporate sustainability fifth consecutive decade commitment year roche recognise roche chil dow jones sustainability dren walk roche indice djsi group employee worldwide gen leader sustainability erated million pharmaceutical biotech swiss franc support nology life science indus vulnerable child malawi try rest world roche medicine patent roche reach total pool sign agreement woman key increase access valcyte position year treat cmv infection ahead diversity hiv patient major cause goal blindness diagnostic roche launch cobas roche acquire constitution fully automate lab medical investor inc solution improve labo develop innovative ratorys throughput test hematology testing sys efficiency enable healthcare tem system design professional fast provide fast reliable treatment decision accurate diagnosis blood relate disease cobas hpv test cervical new cancer test cancer screening receive screen diagnose breast prix galien greece cervical lung thyroid award good diagnostic cancer launch tool prix galien awards year consider equiva lend nobel prizes scientific communityhow difference roche innovationdriven business invest billion swiss franc research development produce stateoftheart medicine diagnostic test provide significant medical benefit topselling pharmaceutical millions chf mabtherarituxan avastin herceptin lucentis xeloda oncology oncology oncology ophthalmology oncology immunology nonhodgkin colorectal breast herpositive wet agerelate colorectal colon lymphoma lung kidney ovarian breast cancer macular degeneration breast cancer unlike common cancer cancer gliobla aggressive macular edema follow chemother lymphatic system toma type brain form breast cancer e retinal vein occlusion apy cancer treatment chronic lymphocytic tumour work affect diabetic macular give leukemia starving tumour patient diagnose edema disease intravenously xeloda common form blood supply disease cause severe dam pill stop cancer blood cancer approve treat age eye cell grow rheumatoid arthritis herpositive gastric decrease size cancer tumour pharmaceutical oncology immunology infectious disease ophthalmology neuroscience sale chf billion roche new molecular entity pipeline hope day compound medicine disease currently treatment option roche produce generic biosimilar nonprescription drug sale growth constant exchange rate average fullyear topselle diagnostic millions chf cobas e accuchek nano cobas c benchmark ultra cobas ampliprep immunodiagnostic smartview clinical chemistry tissue diagnosis virology blood glucose meter broad portfolio meter broad portfolio advance stain early modular instrument design selfmoni modular instrument tissuebase test detection viruse software wide tore blood glucose software wide visualise identify hiv human range immunology help people range test base molecular target papilloma virus base test include diabete clinical chemistry cancer tissue hepatitis b c viruse test tumour blood glucose level include test thy target help identify test result help physi heart disease control roid dysfunction cho make cian identify lesterol triglyc eride specific cancer grow optimal therapy important test en able doctor patient assess health choose good therapy status example patient heart diagnostic immunoassays diabete clinical chemistry pcr test tissue cancer test sale chf billion roche develop diagnostic system test lab customer medical practitioner patient healthcare system division strategy build pillar testing efficiency medical valuemake innovation accessible roche work partnership world sure patient possible benefit medicine diagnostic test example initiative find annual report work treat strive healthcare help fight newborn baby risk philippine reach hepatitis b china hiv subsaharan africa overcome hurdle work helping establish private egypt improve access healthcare budget health insurance cancer treatment europe china support healthcare support people diabetes make sure system peru treat cancer pakistan access medicine uscontent key figure letter chairman board director key event honour dr franz b hum corporate executive committee difference letter ceo business review group result outlook strategy market environment research development highlight access external innovation diagnostic conduct responsible r manufacture procurement pharmaceutical procurement diagnostic quality compliance market medical value make innovation accessible customise solution education healthcare professional responsible business strengthen compliance manage risk crisis increase transparency safeguard patient safety people prioritie performance leadership diversity talent attraction retention community involvement humanitarian social project science education natural disaster support art culture safety security health environment occupational accident disease water management energy management air emission security corporate governance remuneration report corporate governance remuneration report web independent assurance report roche corporate responsibility reportingletter shareholders franz b humer dear shareholder letter chairman give great pleasure report excellent performance roche group challenge increasingly costsensitive environment focus target medicine diagnostic test allow expand strong market position significantly improve net income light strong performance board director propose th consecutive year increase dividend roche post strong result group sale increase todays healthcare challenge roche develop medicine constant exchange rate billion swiss franc improve prolong life patient swiss franc overall net income grow sharply save significant resource part health billion swiss franc swiss francs care sector end diagnostic testing increasingly play ing criti cal role detection disease monitor increase demand medicine diagnostic treatment modality development target test especially new cancer treatment launch treatment reduce overall cost healthcare year pipeline system strong industry result reaffirm roche strategy focus innovation medicine diagnos roche strength significant biotech knowhow tic result competitive advantage devel expertise area open world new possibility ope medically differentiate product strength treat disease bring real medical breakthrough pa important future target cost tient leadership biotech result targeted effective treatment key role play overcome acquisition genentech merger transac roche annual report letter shareholderstion big impact pharmaceutical march majority swiss citizen vote refer en business diagnostic market leader dum favour set change swiss constitution acquire boehringer mannheim past governance regulation list company roche year systematic focus innovation selective decide comply new regulation early transaction roche world lead company require propose change company article oncology global number vitro diagnostic incorporation year agm important one focus pharmaceutical diagnostic enable include chairman board member succeed increasingly competitive marketplace board director member remuneration committee elect annually share hold er doubt mind roche unique company furthermore propose implement b ind ing vote true today decade ago remuneration ahead mandatory date join unique culture unique majority ownership original found family light strong performance board allow longterm view pursue longterm di rec tor propose dividend increase swiss strategy develop innovative product hoffmann franc share nonvoting equity security oeri family sincere gratitude support swiss franc make th dividend increase give career roche year approve half net income distribute shareholder dividend selection dow jones sustainability indi ce world sustainable healthcare company like thank roche shareholder trust indication roche right track roche past year immensely enjoy work single distinction fifth year row board management employee roche rating recognise commitment behave ethically proud accomplish responsibly create longterm value stake roche truly great company holder foundation roche rocksolid predece sor house roche finish com pany automatic right prosperity need earn confident new generation leader executive committee everin schwan leadership board director continue build franz b humer chairman board successful business enrich roche culture choose annual general meeting agm march moment step chairman roche group work pharmaceutical industry year half roche head pharmaceutical division ceo chairman board forthcome agm roche board director pro pose christoph franz serve non exec utive director roche board elect chair man board christoph franz roche chairman outstanding personal quality impre sive record head major global company sure extensive experience exceptional worldwide network great asset letter shareholder roche annual report dr franz b humer head pharmaceutical division member board director roche holding ltd chief operating officer chief executive officer chief executive officer chairman board director roche holding ltd chairman board director roche holding ltdin honour dr franz b humer thank franz humer great endure success roche achievement employee especially result farsighte strategic operational course set past year dr franz b humer dr humer retire chairman annual general meeting reason pay tribute exceptional career company dr humer join roche head pharmaceutical division member board director year later name chief operating officer assume overall responsibility chief executive officer characteristic persistence knowledge short see evolu focus activity pharmaceu tion industry tical diagnostic business peer strength turn vation shortterm thinking vision reality eye quarter result little interest action like warmly thank guide clearly formulate strategy franz b humer behalf board equally comprehensible em director oeri hoffmann ployee shareholders alike family grateful dr humer experience knowledge follow retirement fritz company owe lot retire continue advise roche board gerber franz b humer elect chairman roche today un chair man board serve dispute leader oncology large role severin bold decision schwan name ceo dr humer challenge pe year knowledge strategic riod company begin vision impressive management skill century franz b humer believe strong personality dr humer value close collaboration shape continue shape pharmaceutical diagnostic andr hoffmann company area common vicechairman board directorsletter shareholders severin schwan dear shareholder exceptional year innovation rochewith perjeta kadcyla bring new generation treatment patient aggressive type breast cancer receive approval gazyva treatment patient common type leukemia grow demand medicine diagnostic reflect strong operating result exceed financial target year roche continue positive growth trend past year approval united states europe year sale pharmaceutical division rise kadcyla novel medicine represent major break total billion swiss franc strong growth patient suffer aggre oncology portfolio actemra rheumatoid sive herpositive breast cancer antibodydrug arthritis lucentis eye medicine diagnostic sale grow conjugate highly potent chemotherapy drug ahead global vitro diagnostic market increase attach antibody precisely target cancer cell billion swiss franc drive strong demand c li n significantly reduce effect systemic chemo cal laboratory core operating profit grow billion therapy swiss franc core earning share increase constant exchange rate swiss franc milestone eu approval sub cutaneous form herceptin reduce hospital time importantly future continue good patient perjeta combination herceptin receive prog ress product pipeline excite milestone groundbreaking approval united states roche annual report letter shareholderstreatment patient herpositive breast cancer time access innovative patent protect treat surgery medicine significantly improve survival ment challenge global health issue rate woman herpositive breast cancer close heart create truly innovative medicine diagnostic test mean little not work improve standard care reach patient aim person need hematology tumour extend franchise mabthera product able access benefit rituxan gayzva treatment chronic end work world healthcare author lymphocytic leukemia medicine receive approval itie government stakeholder break record time fda grant priority review barrier access healthcare find breakthrough therapy designation initiative improve access report pipeline number exciting compound new look forward expect lowto midsingle digit molecular entity total late stage group sale growth constant exchange rate tar twothird latestage compound get core eps grow constant exchange rate ahead develop companion diagnostic demonstrate sale expect increase dividend progress make personalised healthcare confident roche future large nature innovation involve risk setback culture innovation thrive ultimately innova way disappointment discontinua tion depend talented dedicated employee tion trial aleglitazar promise medi function country like thank roche cine treat diabetesrelated heart condition employee professionalism commitment passion realign research effort focus field cancer immunology autoimmune disease ophthalmology infec exciting future small foundation tious disease neuroscience lay chairman franz humer stepping chairman roche group year investment r billion swiss franc roche leadership roche number high world remain firmly commit pharmaceutical company biotechnology oncology strategy innovation focus science core diagnostic privilege work strength deep understanding underlie molecular greatly benefit guidance personally behalf cause disease enable find target solution executive committee roche employee rootcause disease biotechnology product like thank franz humer invaluable contribution account threequarter pharmaceutical sale roche diagnostic test discovery development drug long expensive pro cess uncertain outcome patent protection funda mental researchbase company patent mean reward creation intellectual property temporary market exclusivity ensure severin schwan resource invest future patent chief executive officer expire new medicine accessible mankind low price forever proud roche medicine include world health organization essential medicine list offpatent freely available low cost core list comprise effective safe costefficient medicine believe require basic healthcare system product exist today robust patent system encourage invest ment innovation develop ment truly innovative medical product contract society letter shareholder roche annual report board director dr franz b humer andr hoffmann dr andreas oeri representative shareholder group representative shareholder group pool voting right pool voting right prof pius baschera prof sir john irving bell paul bulcke william burns dr christoph franz dame deanne julius dr arthur levinson dr severin schwan peter r voser board director december prof beatrice weder di mauro roche annual report board directorsboard director year birth elect board director dr franz b humer e chairman andr hoffmann c e vicechairman dr andreas oeri e prof pius baschera e prof sir john irving bell b e paul bulcke b e william burns e dr christoph franz c e dame deanne julius b e dr arthur levinson c e dr severin schwan peter r voser c e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson board director forthcoming annual general meeting agm march roche board director propose christoph franz elect chairman board christoph franz nominated succeed franz b humer announce agm march stand reelection board director roche annual report corporate executive committee dr severin schwan daniel oday roland diggelmann dr alan hippe silvia ayyoubi dr gottlieb keller osamu nagayama dr richard scheller prof john c reed corporate executive committee december dr stephan feldhaus dr sophie kornowskibonnet roche annual report corporate executive committeecorporate executive committee year birth position corporate executive committee dr severin schwan ceo roche group daniel oday coo division roche pharmaceutical roland diggelmann coo division roche diagnostic dr alan hippe chief financial officer silvia ayyoubi head group human resources dr gottlieb keller general counsel enlarge corporate executive osamu nagayama chairman ceo chugai committee dr richard scheller head genentech research early development gre prof john c reed head roche pharma research early development pre dr stephan feldhaus head group communications dr sophie kornowskibonnet head roche partnering secretary corporate executive committee perolof attinger statutory auditor kpmg klynveld peat marwick goerdeler sa reporting year roche holding ltd kpmg ag auditor charge john morris ian starkey chief compliance officer dr urs jaisli corporate executive committee john c reed appoint head pharma research early development pre april member enlarge corporate executive committee corporate executive committee roche annual report break barrier roche business report make innovation accessibleaccess healthcare remain global challenge healthcare vary dramatically country country country sophisticated medicine test widely available whilst little basic infrastructure establish market medicine year available patient roche work partnership world try difference help break barrier healthcare run programme tailor specific local need support disease education bring screen remote area product affordable example initiative find annual report make innovation accessible roche annual report make innovation accessible work healthcare budget europe make sure access medicine support healthcare system peru treat cancer roche annual report make innovation accessible helping establish private health insurance cancer china help fight support people hepatitis b diabete china pakistan overcome hurdle egypt improve access treatment strive healthcare philippine reach work treat newborn baby risk hiv subsaharan africa make innovation accessible roche annual report work treat newborn baby risk hiv roche business report make innovation accessiblesubsaharan africa africa mothertochild transmission main cause hiv child treatment child hiv die age age early infant diagnosis number test conduct year innovative testing technology expand access care remote area early hiv diagnosis mean baby right treatment stay healthy end roche support intro duction new way test blood sample dry card able effectively test hiv result process stateoftheart procedure doctor notify test result immediately collection card expand access hiv diagnosis remot e area southern africa roche continue work number organisation public private partner ship ensure subsequent medical care baby hiv make innovation accessible roche annual report swiss franc core earning share roche annual report business review exceed financial target deliver strong sale growth oncology immunology ophthalmology improve cash flow reduce net debt roche annual report business review key figure group sale million chf cer core operate profit million chf cer ifrs net income million chf cer millions chf change sale cer chf group sale pharmaceutical division diagnostic division core operate profit pharmaceutical division diagnostic division operate free cash flow core earning share chf group result outlook roche group post strong overall result swiss franc rise number currency exceed financial target year group sale mainly japanese yen dollar lead negative increase billion swiss franc reflect positive impact result report swiss franc demand oncology product especially cancer product avastin instrument test professional diagnostic business pharmaceutical strong sale growth sale increase diagnostic sale grow united states emerge market main regional growth oncology immunology driver europe perform challenging market ophthalmology product condition group core operating profit grow billion swiss franc core earning share ep increase sale pharmaceutical division increase constant exchange rate swiss franc billion swiss franc strong demand prod uct breast cancer franchise cancer medi cines avastin mabtherarituxan actemraroactemra rheumatoid arthritis eye medicine lucentis state growth rate calculate cer formance key growth product compensate constant exchange rate average fullyear ifrs international financial reporting standard price competitive pressure mature product roche annual report business reviewpegasy strong sale performance lead increase actemraroactemra grow reach sale core operate profit billion swiss franc billion swiss franc time pharmaceutical sale product billion chf main regional sale growth driver united states key emerge market united states post sale growth share rise sale sale increase key emerge vs chfm cer market demand particularly strong china mabtherarituxan brazil europe sale rise despite ongoing avastin pricing pressure strong sale avastin japan herceptin sale high spite termination comar lucentis keting agreement evista osteoporosis medicine exclud xeloda ing impact sale growth japan tarceva pegasys actemraroactemra pharmaceutical sale region cer product total p harmaceuticals united states europe cancer medicine account majority pharmaceutical japan sale product treat international herpositive breast cancer sale franchise consist herceptin newly launch medi cine perjeta kadcyla grow good uptake perjeta kadcyla grow use herceptin key emerge market china brazil new pharmaceutical product strengthen outlook hematology avastin treat different type cancer product franchise important launch perjeta important growth driver sale rise kadcyla herpositive breast cancer launch largely strong sale treatment ovarian cancer gazyva chronic lymphocytic leukemia cll europe increase use colorectal cancer europe common type blood cancer united states blood cancer rheumatoid arthritis med icine mabtherarituxan significant contribution perjeta gain european approval advance herpositive growth increase sale breast cancer march approval treat positive breast cancer surgery september perjeta addition oncology product pharmaceutical division combination herceptin approve pre support sale eye medicine lucentis surgical neoadjuvant breast cancer treatment united grow sale rheumatoid arthritis drug state secure regulatory backing kadcyla united states europe japan make antibodydrug conjugate adc approve treat advanced pharmaceutical sale therapeutic area cer herpositive breast cancer adc targeted cancer medicine attach certain type cancer cell oncology deliver chemotherapy directly result highly potent treatment few adverse effect immunology addition receive european approval subcu infectious disease taneous formulation herceptin new formulation help significantly reduce administration time relate ophthalmology neuroscience therapeutic area roche seven key emerge market e brazil china india mexico russia south korea turkey business review roche annual report treatment cost associate traditional intravenous diagnostic sale business area cer method administration professional diagnostic gazyva approve united states november diabete care fda grant breakthrough therapy designation result strength datum latestage trial molecular diagnostic lifethreatening nature cll latestage trial tissue diagnostic investigate gazyva nonhodgkin lymphoma common cancer lymphatic system diffuse large bcell lymphoma ongoing roche spend billion swiss franc pharmaceutical region contribute growth asiapacific latin research development area oncology immu america grow doubledigit rate sale rise nology infectious disease ophthalmology neuroscience asiapacific china latin america pharmaceutical pipeline significant pro europe middle east africa emea region ac gress oncology area ophthalmology count half division business grow immunology pipeline currently new molecular enti north america sale increase strong sale growth tie clinical development latestage de professional diagnostic business offset sale velopment base promising midstage datum select decline diabetes care japan sale grow nme latestage development com pound oncology immunology compound ophthalmology diagnostic sale region cer europe middle east africa emea good growth instrument north america test clinical asiapacific laboratory latin america japan diagnostic division grow ahead global vitro diagnostic market sale increase billion swiss franc growth mainly drive sale profes new diagnostic product sional diagnostic business area strengthen diagnostic division spend billion swiss franc division position market leader core operating profit research development diagnostic instrument diagnostic division rise billion swiss franc test roche launch major product include instru division core operate profit margin remain stable ment advance lab automation new device diabete management addition test menus professional diagnostic division large business area exist instrument key introduction benefit strong growth immunoassay business cobas preand postanalytic instrument new sale blood glucose monitoring product decrease fully automate workflow series automates routine labora result reimbursement cut key market include tory task increase costefficiency lab reduce united states result diabete care business unit manual handling sample continue implement restructuring measure ensure long term profitability molecular diagnostic business area grow nextgeneration blood glucose meter accuchek active growth underlie business main accuchek avivaperforma launch market taine position market leader strong growth accuchek aviva expert system receive regulatory blood screening business test human papilloma clearance united states virus hpv sale tissue diagnostic especially advanced staining product rise roche annual report business reviewmolecular diagnostic receive label expansion test ence business area portfolio product integrate sexually transmit disease ctng market business area diagnostic obtain market clearance europe microbiology test mrsa mssa hsv broad initiative expand production capability biologic medicine actemraroactemra kadcyla late roche obtain market clearance europe perjeta roche recommissione discontinue produc fully automate cellbase cintec plus cytology test tion unit california result reversal previously cervical cancer screen cobas hpv test incur impairment charge contribute ifrs screening cintec p histology test cintec plus net income cytology test roche complete cervical cer screen diagnosis product portfolio iden improve net debt position tify cervical cancer early identify case group operate free cash flow grow constant miss pap smear screen exchange rate swiss franc billion swiss franc result cash flow generate division despite increase inventory relate new product launch positive free cash flow enable roche improve profitability improve group net debt position roche pay cash flow record dividend payment shareholder billion swiss franc operating profit improve core eps rise end december debt take finance ahead sale genentech transaction repay net group core operating profit increase constant debt position group yearend billion exchange rate swiss franc drive strong swiss franc decrease billion swiss franc year sale performance end december net debttoasset ratio marketing distribution cost rise support growth key market united states china patient access programme new product launch research outlook devel opment cost increase billion swiss franc expense oncology neuroscience disease area include trial recently launch product roche expect low midsingle digit group sale pipeline product growth constant exchange rate core ep target grow cer ahead sale roche expect roche core earning share eps exclude non increase dividend core item global restructuring charge amorti sation impairment goodwill intangible asset rise swiss franc share drive strong operating performance low financing cost debt incur finance genentech transaction net income grow strongly ifrs net income rise billion swiss franc swiss franc good operating performance low financing cost significantly low global restructuring expense roche complete operational closure nutley site schedule end restructure measure improve efficiency profitability diabete care business area underway apply sci business review roche annual report market environment age population rise healthcare cost grow economic access healthcare pressure new opportunity emerge market driv part develop world lack resource infra e rapid change healthcare market new structure education mean people scientific discovery technology provide unprece basic healthcare healthcare spending capita vary dent insight disease mechanism draw significantly country country scientific insight expertise pharmaceutical diag significantly influence access healthcare nostic roche respond market challenge devel ope innovative product prevent diagnose treat access healthcare relate cost disease important issue united states implementation major provision patient protection affordable care act continue develop country government face budget pressure challenge assumption healthcare system universal access new medicine reflect pressure reimbursement approval healthcare system face challenge population access healthcare remain global challenge world grow old patient expect healthcare provider people lead un healthy lifestyle treatment patient suffer number medical issue complex cost rise time budget tighten effec tive allocation limited resource vital healthcare sys tem particularly longterm market trend suggest challenge likely intensify unmet medical need twothird disease treat adequately treat expect agerelate illness usd usd cancer alzheimer disease cardiovascular prob usd usd lem increasingly major challenge healthcare usd system effective diagnose medicine essential datum reduce overall burden disease society total private public capita expenditure healthcare usd average exchange rate source value money response government try adapt healthcare system tackle healthcare need cost control payer play central role deter mine medicine doctor patient stringent criterion decide product necessary financial support health tech nology assessment assessment medical social ethi cal economic implication new medicine test increasingly important healthcare provider try determine treatment available patient cost roche annual report business reviewour market role healthcare industry roche sale pharmaceutical product pharma ceutical market usd billion estimate grow annually growth expect come innovation emerge market mature global pharmaceutical diagnostic industry con markets north america europe japan expect tribute efficient effective healthcare solution grow period major spending medicine account onetenth product area oncology expect grow annually total healthcare bill develop country worldwide year rise slow pace overall spend healthcare recent year pharmaceutical market sale usd billion spending healthcare medicine cagr total healthcare expenditure capita index north america europe japan row source im health prognosis sep roche analysis compound annual growth rate total healthcare expenditure capita index total medicine expenditure capita index roche sale diagnostic instrument test source im health prognosis sep roche analysis vitro diagnostic market value estimate usd billion sale market expect grow come year develop market innovative medicine enable disease treat fast emerge market important growth effectively low cost new treatment reduce driver expand number patient treat hospital reduce length diagnostic market professional diagnostic market hospital stay diagnostic testing enable fast expect grow overall market rate blood accurate diagnosis disease lead low cost glucose monitoring expect grow delay ultimately well medical outcome diagnostic testing currently account healthcare spending medical decision depend diagnostic market sale usd billion vitro diagnostic test cagr north america europe japan row source roche estimate validate independent ivd consultancy compound annual growth rate business review roche annual report strategy leader oncology treatment fur ther improve standard care herpositive breast cancer launch kadcyla perjeta work improve standard care hematol roche strive difference live million ogy move mabtherarituxan develop new medi patient world medicine vitro cine like gazyva diagnostic test believe product provide significant medical benefit patient doctor build strength biotechnology efficiency gain laboratory health economic benefit believe enormous potential modern biological payer science understand underlie mechanism grow ability develop target treatment focus patient important contribution manage chal patient centre business model lenge currently confront healthcare system strength million people receive treatment biotechnology research development manufacturing product million people treat roche prod mean ideally equip translate insight cell uct offpatent essen biology new treatment test tial drug list patient receive access inno vative treatment clinical trial programme roche world big biotechnology company current product improve prolong live important biopharmaceutical medicine market investiga disease area cancer arthritis hepatitis diabete tional biopharmaceutical pipeline seven selling medicine biopharmaceutical lead set new standard care diagnostic company diagnostic test currently invest billion swiss franc research supply base biotechnology plan vigorously development year create medically differentiate continue research investment area product pursuit excellence science research announce major investment million swiss franc focus area oncology immunology ophthalmol biotech production capacity ogy infectious disease neuroscience innovation internal hub worldwide network give research activity breadth external network diversity flexibility roche pioneer partner pipeline market product origi nate external partnership roche pharmaceutical company develop global network dedicate specialised research centre operate high degree autonomy ensure diversity scientific approach combine critical mass large research company flexibility small research unit roche group independent research organisation pharma research early development genentech research early development chugai japan diagnostic division form hub internal innovation network complement strong inhouse capability ex tensive network external partnership partner roche annual report business reviewdriving personalise healthcare make innovation accessible personalised healthcare phc provide right despite remarkable breakthrough diagnose treat therapy right group patient right time phc disease ensure patient access break enormous potential combating cancer dis through remain significant challenge main contribu ease effectively draw insight patient tion challenge deliver innovation develop genetic biological difference medicine medicine diagnostic prolong improve people increasingly tailor specific patient population life work different partner population identify modern diagnostic test reduce barrier prevent people diagnose combine strength pharmaceutical diagnos treat product healthcare system tic prove expertise molecular biology well world different complex equip company drive personal single global approach provide tailor solution ise healthcare allow doctor pinpoint patient address need individual country include inno likely benefit drug enable healthcare vative pricing model personalise reimbursement model system allocate resource effectively patient access programme health infrastructure health education programme aim person need roche company bring targeted treat product able access benefit ment patient launch herceptin recently zelboraf perjeta kadcyla heart approach use biomarker predict therapy outcome clinic refine process develop drug diagnostic twothird latestage compound develop com panion diagnostic addressing healthcare challenge healthcare challenge roche strategic response unmet medical need exist product cancer arthritis hepatitis diabete improve patient care future target treatment cancer immunology infectious desease ophthalmology neuroscience value money truly innovative medicine diagnostic test demonstrable medical economic benefit personalise healthcare target treatment optimise patient care access healthcare innovative pricing model patient access programme partner public private healthcare provider improve access product business review roche annual report strive healthcare reach roche business report make innovation accessiblephilippine increase access roche breast cancer medicine herceptin reduce price working sure medicine affordable philippine public healthcare system cover cost medicine patient pay pocket treatment especially sophisticated medicine majority unaf fordable address problem roche philippine develop socialised pricing programme consider individual affordability level patient doctor prescribe cancer medicine external agency make financial assessment discount pre scribe medicine grant base patient capacity pay make innovation accessible roche annual report collaboration pharmaceutical diagnostic roche annual report research development launch new medicine fight breast blood cancer explore new way immune system tackle cancer enter key partnership drugresistant bacterial infection roche annual report research development key figure core research development expenditure roche group million chf cer sale pharmaceutical million chf cer sale diagnostic million chf cer sales cer constant exchange rate average fullyear highlight pharmaceutical milestone compound indication approval gazyva previously untreated chronic lymphocytic leukemia kadcyla herpositive metastatic breast cancer perjeta herpositive breast cancer neoadjuvant approval eu herceptin subcutaneous herpositive breast cancer kadcyla herpositive metastatic breast cancer second later line perjeta herpositive metastatic breast cancer line key phase iii trial result avastin advanced cervical cancer gog avastin newly diagnose glioblastoma multiforme avaglio gazyva chronic lymphocytic leukemia cll kadcyla herpositive metastatic breast cancer thresa diagnostic major product launch cobas accuchek active capctm hcv test key clinical study result prognosis preeclampsia test interim result abacus study diabete approval obinutuzumab ga trade gazyva grant united states time publication harness diversity research early development carry maximise r activity genentech research early development gre roche pharma research early development pre activity support chugai japanese year invest heavily research develop subsidiary external partner currently new medicine diagnostic test focus oncology alliance company institutes immunology ophthalmology infectious disease neuro outside company compound successfully develop science draw expertise outside gre pre chugai partner global late company maximise output ensure invest stage development unit ment yield sustainable result roche annual report research developmentwe strive excellence science basis deep accelerate approval perjeta united understanding underlie biology disease state treatment herpositive breast cancer prior end build extensive expertise molecular surgery neoadjuvant perjeta combine cellular biology past decade truly medicine herceptin chemotherapy approve standing cell behave replicate interact treat advanced herpositive breast cancer able modulate biochemical pathway speed approval perjeta neoadjuvant set cell information energy need grow exceptional year medicine knowledge understand vital devel secure back early use initial approval opment new medicine number disease include l aterstage indication cancer perjeta grant approval phase ii neosphere entire process drug development underpin trial show nearly people receive perjeta herceptin diagnostic division play invaluable role chemotherapy evidence tumour time develop companion diagnostic test mean surgery know pathological complete response pinpoint patient likely respond medicine pcr perjeta approve neoadjuvant breast early development process allow design cer treatment united states effective efficient trial well safe medi approve base pcr datum cine approach crucial personalise healthcare strategy currently investigate combination perjeta kadcyla treat advanced herpositive breast cancer currently potential new medicine pipeline expect result phase iii marianne trial read potential diagnostic instrument test devel second half opment twothird latestage compound develop companion diagnostic hematology franchise boost launch gazyva chronic lymphocytic leukemia cll recognise innovative common form blood cancer phase iii headtohead company worldwide thomson reuters genentech study cll demonstrate clear efficacy benefit gazyva corporate award economist innovation awards mabtherarituxan report encourage datum oral smallmolecule bcl inhibitor rg latestage development rg bcl inhibitor plan start early cll phase ii trial nonhodgkin lym phoma begin half pharmaceutical significant progress antipdl antibody strengthen herpositive breast rg new type cancer treatment design restore cancer franchise hematology portfolio patient immune system able fight tumour innovative product area cell molecule move latestage development nonsmall cell lung cancer promising phase efficacy datum launch kadcyla united states europe present rg develop advanced herpositive breast cancer particularly aggre investigational companion diagnostic sive form disease affect people treat cancer type com bi breast cancer bring revolutionary new treatment option nation exist cancer medicine physician patient avastin zelboraf kadcyla antibodydrug conjugate adc decide stop development aleglitazar regular kind approve treat type breast cancer safety review alecardio phase iii trial investigate adc target cancer medicine attach certain compound type diabete detect safety signal lack type cancer cell deliver chemotherapy directly result highly potent medicine few adverse effect rg list gdcabt clinicaltrialsgov rg list mpdla clinicaltrialsgov research development roche annual report efficacy mean long compound newly diagnose slowgrowe nhl gallium cardiovascular disease latestage pipeline asset latestage study evaluate gazyva combination ben early development evaluate damustine type chemotherapy versus bendamustine treat patient nhl respond previous treatment gadolin goya trial expect read result gallium gadolin oncology study world lead provider cancer drug roche gazyva type ii anticd medicine glyco develop medicine treat number different cancer engineer mean specific sugar molecule cancer breast skin colon ovary lung modify drug change way interact hope development new medicine area bodys immune cell gazyva attack target cell help patient live long well life directly bodys immune system step fight blood cancer investigate gazyva combination rg half blood cancer occur year gdc bcl inhibitor bcl protein highly lymphomas cancer lymphatic system lymphatic express cll indolent nhl aggressive lym system lymph node neck armpits groin phomas variety solid tumour bcl inhibitor chest abdoman immune system lympho develop abbvie design promote mas cause abnormal growth lymphocyte type apoptosis latestage development rg plan white blood cell start begin phase datum show overall response rate patient nhl nhl common cancer lymphatic system return initial treatment relapse fail cll common type leukemia western respond give treatment refractory datum show world cause death worldwide year overall response rate patient relapse refractory cll nhl cll bcell malignancie high level protein call cd find surface malignant pipeline potential hematology medicine include bcells protein mabtherarituxan antibodydrug conjugate adc polatuzumab vedotin new blood cancer medicine gazyva obinutuzumab anticdb phase ii trial currently evaluate com design target pound combination mabtherarituxan launch mabtherarituxan currently standard immune system fight cancer care nhl cll treat nearly mil immunotherapy new approach fight cancer lion cancer patient hope able work overcome certain mechanism interfere improve mabtherarituxan gazyva bcl bodys ability destroy tumour cell type treat inhibitor rg ment result longterm durable response transform way treat cancer smart combination far datum gazyva encourage result target medicine help support phase iii cll trial show gazyva combination immune response fight cancer success field chlorambucil type chemotherapy help people result cancer cure cancer previously untreated cll live nearly year long chronic disease disease worsen treat mabtherarituxan type chemotherapy study investigat antipdl antibody rg move latestage ing dose safety gazyva different chemotherapy development nonsmall cell lung cancer promising regimen cll ongoing phase datum show efficacy durability response patient stop respond therapy headtohead phase iii study compare gazyva mabtherarituxan currently conduct investigate gazyva combination chemotherapy firstline treatment diffuse large bcell lymphoma goya roche annual report research developmentcombining therapy pdl molecule avastin zelboraf number optimal response different type cancer consider gazyva bcl inhibitor treat certain type blood cancer combination different cancer therapy likely play key role way tackle cancer moment evidence drug block particular disease pathway limited period time cancer cell find new pathway allow continue grow aim cut lifeline possible cancer cell number different medicine combat disease hope approach reduce resistance increase length time patient respond treatment explore approach investigate combination tarceva onartuzumab lung cancer zelboraf mekinhibitor cobimetinib skin cancer anti immunotherapy currently adcs clinical development different type cancer encourage earlystage clinical datum cancer cell immune cell present rg antinapib rg anti steap see promising phase result rg antimuc patient advance muc express platinumresistant ovarian cancer rg evaluate patient advance non squamous nonsmall cell lung cancer ovarian cancer resistant platinumbase chemotherapy rg investi gate patient advance castration resistant prostate cancer prostate cancer respond medical castration certain kind immunotherapy design help activate antibodydrug conjugates immune system block stop sign prevent immune cell destroy cancer cell antibodydrug conjugate combine boost power antibodies antibody chemotherapy deliver medicine directly cancer cell continue development antibodydrug conjugate adc follow successful launch kadcyla adcs allow target delivery chemotherapy cancer cell chemotherapy link antibody result increase efficiency few effect traditionally associate chemotherapy hair loss nausea infection rg list dniba clinicaltrialsgov rg list dstps clinicaltrialsgov rg list dmuca clinicaltrialsgov research development roche annual report tackle women develop avastin treat advanced cervical health issue cer approve avastin treat recurrent persistent disease account case treatment advance cervical cancer roche invest medicine diagnostic test year latestage datum present american help significantly improve health woman society clinical oncology show avastin plus chemo demand breast cancer medicine robust therapy improve median overall survival nearly month recently launch avastin europe latin america asia month treat advanced ovarian cancer disease currently treatment option available diagnostic division present key datum pre eclampsia test test design easy work potential test treatment cervi doctor predict woman great risk develop cal cancer common type cancer woman e complication pregnancy preeclampsia occur approximately woman die illness year pregnancy lifethreatene case occur develop country mother baby especially diagnose cervical cancer case cause human papilloma virus effectively prevent well screening vaccination catch early stage cervical cancer treat successfully diagnostic division building success recently launch hpv test improve screen cervical cancer cintec plus cytology test design detect early change cell cervix woman treat cancer develop cobas hpv test cintec histology test cintec plus cytology test roche complete cervical cancer screen diagnosis portfolio help woman healthcare professional tackle cervical cancer avoid case miss screening pap smear develop antibodytargete cytolytic fusion pro resistant exist treatment able penetrate tein cfps complement adcs contrast adcs brain unlike therapy important kill proliferate tumour cell protein patient advanced lung cancer die destroy cell divide mean cancer spread brain alectinib move tumour resistant standard antiprolifer latestage development grant breakthrough ative agent day treat therapy designation fda encourag ing efficacy early study patient cancer possible new treatment lung cancer alkpositive develop compound com alk inhibitor alectinib smallmolecule compound panion diagnostic chugai develop patient anaplas tic lymphoma kinase alkpositive nonsmall cell lung cancer nsclc account approximately nsclc case drug deliver significant benefit patient alkpositive lung cancer active tumour roche annual report research developmentimmunology affect child teenager early age onset mean cost patient healthcare system society understand biology characterise patient high prevalence higher industrialise country subgroup disease believe homo emerge asiapacific region possibly geneous hope develop new medicine westernisation diet ibd associate range disease include severe asthma inflammatory significant morbidity include surgical intervention hospital bowel disease isation increase risk colon cancer work provide relief severe asthma develop etrolizumab treat crohns disease million people suffer asthma worldwide ulcerative colitis symptom crohns disease die asthma year high prevalence affect gastrointestinal tract include significant europe united states australia affect abdominal pain diarrhea weight loss lack energy population mild moderate form undetected extended period time symptom disease treat adequately current medication vague case people mal million people united states euro nourish body long able absorb key pean union suffer severe uncontrolled asthma nutrients clinical presentation ulcerative colitis asthmatic burden disease extensively limit affect colon acute symptom include fre quality life frequent shortness breath poor exer quent bloody diarrhea abdominal pain lack energy cise tolerance asthma attack effect systemic crohns disease ulcerative colitis increase patient steroid treatment risk development colon cancer time currently develop lebrikizumab new treatment current treatment option modestly effective patient severe uncontrolled asthma lebrikizumab come significant effect etrolizumab gutselec latestage trial novel humanise monoclonal antibody tive antibody beta integrin uniquely bind design target function interleukin cytokine alphabeta alphaebeta gut selectivity dual increase patient asthma think mode action result important safety efficacy causal mechanism airway inflammation advantage agent integrin play important role migration cell interact en inhale steroid current cornerstone therapy vironment etrolizumab programme evaluate alphae people uncontrolle asthma respond expression gut potential diagnostic biomarker high dose inhale steroid second controller etrolizumab move latestage development longacte beta agonist patient benefit lebrikizumab ophthalmology key lebrikizumab development programme use companion diagnostic test identify people likely benefit medicine difficult mea sure building ophthalmology portfolio potential interleukin lung blood necessary new treatment agerelate macular degeneration amd find surrogate interleukindriven inflammation seek develop medicine help prevent blind lung researcher identify serum periostin suitable sur ness rogate base phase ii trial periostin appear iden tify patient likely benefit lebrikizumab meeting unmet medical need amd disease associate age gradually result phase iii trial start expect destroy sharp central vision central vision need global filing plan year object clearly common daily task read drive amd lead cause blindness adult new treatment inflammatory bowel disease year age develop world form inflammatory bowel disease ibd chronic disease latestage amd neovascular wet amd geographic gastrointestinal tract commonly present crohns atrophy ga ga characterise irreversible loss disease ulcerative colitis ibd affect people primarily retinal tissue macula result permanent blind spot tween age year onwards patient central vision research development roche annual report geographic atrophy progression patient perspective resistant infection responsible usd billion excess healthcare cost usd billion societal cost usd mil lion additional hospital day news news news enter partnership deal swissbase polyphor develop pol new class antibiotic de sign treat severe hospitalacquire bacterial infection estimate ga currently affect million cause pseudomona aeruginosa pseudomona aeruginosa people worldwide ga increasingly prevalent account hospitalacquire infection population age united states list dangerous population age year old affect drugresistant microbe pol phase ii stud condition currently approve treatment ies kills pseudomona aeruginosa novel mode action people illness overcome resistance see antibiotic fore potential offer new treatment option num researcher develop lampalizumab treat ga ber lifethreatening infection mahalo phase ii study lampalizumab show reduction rate ga area expansion baseline month pseudomona aeruginosa cause urinary tract infection re patient population treat monthly relative control piratory system infection dermatitis softtissue infection meet primary endpoint trial subpopulation gastrointestinal infection variety systemic infection ga patient identify exploratory biomarker monthly pseudomona infection problem patient lampalizumab treatment demonstrate reduction ga weaken immune system cancer area expansion relative control study aid severe burn patient suffer chronic positive treatment effect complement inhibitor ga disease like cystic fibrosis fatality rate patient group infectious disease high rate multidrug resistant pseudonoma strengthen infectious disease portfolio include molecule illness hepatitis b c influenza development mericitabine danoprevir hepatitis c continue decide develop commercialise danoprevir china ascletis hope partnership help address public health problem provide chinese patient data new treatment option hepatitis c new way treat bacterial infection area particular interest development medicine day fight infection resistant exist antibiotic resistance antibiotic grow problem treatment infectious disease pathogen long antibiotic option anti carabapenemresistant p aeruginosa microbial resistancerelate death occur european union year cost european economy b illion euro annually united states antibiotic httpwwwcdcgovmediarelease efpia review fantimicrobialresistancehtml roche annual report research developmentour scientist explore use antibodybase gressive ms trial fully recruit antici therapy attach antibiotic antibodie antibiotic pate phase iii datum deliver directly site infection investi gational therapy concept expect enter tackle alzheimer disease clinic late look new mechanism treat gantenerumab develop treat patient pro antibioticresistant staphylococcus aureus gram dromal mild alzheimer disease show sign positive gramnegative pathogen increase mild cognitive impairment evidence amyloid resistance currently available antibiotic plaque brain goal early treatment slow progression disease prevent damage brain phase iii scarlet road trial ongoing development diagnostic test help identify neuroscience patient likely respond gantenerumab expect result trial understand brain work signif icantly improve decade work work crenezumab alzheimer number compound mark shift way patient mild moderate alzheimer disease like schizophrenia multiple sclerosis ms alzheim antibody target solid particle beta amyloid er disease neurodevelopmental disorder treat plaque brain freefloate soluble future form abeta protein crenezumab phase ii develop ment investigate api prevention trial take schizophrenia know colombian study study lead banner schizophrenia public health problem affect ap alzheimers institute collaboration national insti proximately world population leading cause tut health disability schizophrenia characterise broad cat egorie symptom negative symptom include social addition gantenerumab crenezumab antiabeta withdrawal lack motivation positive symptom antibodie develop monoamine oxidase inhibitor hallucination delusion cognitive deficit maob alzheimers maob small molecule cur involve memory problem difficulty concentrate rently phase ii development maob inhibitor aim schizophrenia molecule bitopertin firstinclass oral improve cognitive function behavioural problem glycine reuptake inhibitor design improve nmethyld alzheimer patient mild moderate dementia stage aspartate nmda receptor function think diminished people schizophrenia clinical research treatment option trial programme bitopertin call searchlyte comprise neurodevelopmental disorder phase iii study suboptimally control symp pharmaceutical company com tom negative symptom announce mitte find new treatment option individual january phase iii study bitopertin adult neurodevelopmental disorder autism fragile x persistent predominant negative symptom schizo down syndrome currently compound phrenia meet primary endpoint remain clinical trial va rg autism mglu rg study ongoing expect datum later fragile x phase ii development gabaa rg down syndrome phase trial potential new medicine multiple sclerosis ocrelizumab latestage development ms debil itate neurological illness ocrelizumab firstinclass humanise monoclonal antibody design selectively target cdpositive bcell think play important role ms result phase ii trial relapse remit ms show ocrelizumab significantly reduce disease activity measure brain lesion relapse rate phase iii clinical programme consist study patient relapse ms study patient primary pro research development roche annual report diagnostic key companion diagnostic project diagnostic division develop number instrument compound disease biomarker solution improve medical outcome test alectinib alkpositive alk efficient strive strengthen position nonsmall cell lung world lead supplier vitro diagnostic ivds ivds cancer play key role help doctor detect diagnose dis antipdl solid tumour pdl ease select appropriate treatment monitor patient rg sponse care test perform labora gantenerumab alzheimer isease amyloid beta tory point care blood tissue patient lampalizumab geographic trophy complement sample factor cfi lebrikizumab asthma periostin provide medical value mek inhibitor solid tumour braf kra offer test enable patient physician obtain rg nras mutation medically relevant information able improve onartuzumab lung cancer meet expression come patient area recently metmab lot progress development test help doctor treat patient suffer heart disease effectively improve lab efficiency patient safety heart failure result reduced quality life frequent laboratory increase pressure generate reli able hospitalisation complex treatment approach high cost result fast time resource high mortality recent clinical trial show scarce management heart failure improve help elecsys ntprobnp test measure level develop fully automate instrument like cobas ntprobnp blood people suffer heart failure help laboratory efficient processing measuring biomarker doctor determine well increase amount information cobas pro course treatment individual patient guideit study vide short predictable turnaround time blood sample example collaboration industry academia help physician fast treatment decision patient national institutes health united states urgent case prioritise process design ntprobnp guide heart twice speed early version system impor failure treatment believe maintain ntprobnp tantly automation process significantly certain level healthcare professional improve improve patient safety reduce risk sample mixup quality life low mortality rate heart failure patient contamination occur manual handle trial end cobas launch highsensitive troponin test design improve develop cobas cobas come people suspect risk heart laboratorie high demand blood screening attack thank high sensitivity test patient virology test cobas design process ischemic symptom risk future cardiac event sample diagnosis eighthour shift cobas identify early clinical study show handle sample time period test improve early diagnosis heart attack system allow laboratory consolidate assay single platform improve workflow efficiency field molecular diagnostic open number aim launch instrument new treatment option range disease molecular analysis human dna confirm presence disease work new programme cobas gene detect altered gene protein disturb infinity solution help laboratory boost output normal cell function genetic profile new solution launch end patient predict person respond give customer flexibility need thank fully specific treatment see value webbase modular functionality test certain type cancer pipeline rich drug develop companion diagnostic roche annual report research developmentaccesse external breakdown type partner deal innovation product transaction research technology great importance access external innovation collaboration key r strategy roche product outlicense partnering focus strengthen portfolio external innovation ensure partner choice biotechnology company research institute world wide nearly million science engineering researcher partnership result development lead worldwide innovative drug come lab ing drug like zelboraf skin cancer mabtherarituxan academia small biotech company vital certain type blood cancer rheumatoid arthritis tamiflu future continue tap idea influenza xolair asthma actemraroactemra generate outside roche long history successful rheumatoid arthritis roche partnering sign new agreement includ analysis new drug approve fda e product transaction research technology source kneller r nature review drug discovery nov importance new company drug discovery collaboration product outlicense agreement main key transaction january genentech afraxis enter global licensing agreement develop compound undisclosed novel target february genentech rqx enter drug discovery collaboration discovery development novel drug compound undisclose target april roche ascletis enter collaboration advance treatment option chinese patient hepatitis c roche california institute quantitative biosciences qb partner identify fund support earlystage life science startup company san francisco bay area june genentech immunocore enter collaboration discovery development multiple novel cancer target immunocore immtac technology september roche inovio pharmaceutical enter partnership research develop commercialise inovio multiantigen dna immunotherapy target prostate cancer hepatitis b november roche polyphor enter partnership develop commercialise polyphor novel antibiotic pol patient suffer bacterial infection cause multidrug resistant pseudomona aeruginosa bacterium november roche immatic sign collaboration develop commercialise cancer vaccine cancer immunotherapy gastric lung prostate cancer december roche prothena enter worldwide collaboration codevelop copromote antibodie treatment parkinson disease research development roche annual report taine record industry lead dealmaker estimate cost bring new chemical biological partner entity market usd million involve innovative medicine initiative join pharmaceutical industry university hospital small mediumsize enterprise patient organ isation public authority jointly fund euro pean commission pharmaceutical industry current project cover early late stage medicine development address range topic chronic pain anti tuberculosis drug combination roche diagnostic sign new collaboration agreement source j mestreferrandiz j sussex towse r cost new medicine office health economic december hansen external pharmaceutical company develop com wiggin dimasi et al ota dimasi et al panion test drug add exist agreement mestreferrandiz et al enter deal pacific bioscience califor nia develop diagnostic product include sequence sys use new technology develop smart way manage tem consumable base pacific bioscience single vast amount datum different system molecule realtime technology look innovative way design clinical stud ies potentially determine answer early break new ground novel surrogate endpoint improve r productivity pathological complete response early breast cancer minimal residual disease lymphomas geographic atrophy year look smart new way improve r lesion size dry agerelate macular degeneration mag efficiency cost develop molecule bring netic resonance enterography crohns disease market continue rise need screen molecule able identify potential industry collaboration call transcelerate bio new candidate need complex clinical pharma working company simplify trial regulatory requirement stringent process relate clinical trial operation monitor rethink programme multiyear initiative en compass aspect develop medicine conduct responsible r resource develop new medicine patient r activity conduct high ethical approach help contain spending standard publish position paper reduce time take turn compound medicine r activity area genetic stem cell animal include use new technology creation innova research routinely review update position tive trial design access crosspharma knowledge policy research involve human animal external collaboration collect datum need take account scientific development public con help manage entire r process effectively cern explore way leverage new technology clinical trial telemedicine mobile app social medium improve clinical trial critical determine safety efficacy efficiency clinical trial example use social new medicine clinical trial compliant network gather key scientific insight physician good clinical practice guideline international quality stan help design trial effectively exam dard information trial share regulatory ple explore use smart phone broaden authority payer patient involve geographical reach trial future make roche annual report research developmentroche clinical trial statistic contract research organisation work roche behalf number patient clinical trial country classification decrease compare approxi mately animal mouse rat low income middle income overall decrease animal usage reflect impact closure nutley research site new jersey usa upper middle income major research site award continue reaccredi tation status association assessment accredi high income tation laboratory animal care international aaalac source world bank underscoring commitment ensure animal welfare base gross national income capita low income usd low middle income usd usd upper middle income usd usd high income usd clinical trial trial carry high standard regardless world run clinical trial number clinical trial number healthcare centre involve number patient phase iiv clinical trial datasharing policy introduce new datum share policy promote broad sharing clinical trial datum interest scientific progress benefit patient policy include provision clinical study report summary safety report access analysable patientlevel datum way protect patient confidentiality respect role health authority assessment approval drug compromise commercial interest work compa ny develop common approach share patient level datum animal welfare public concern animal research seriously worked maintain high standard animal welfare possible seek alter native use animal computer simulation vitro testing differentiated cell stem cell animal internal research decrease number animal research development roche annual report pharmaceutical pipeline roche annual report pharmaceutical pipeline pharmaceutical pipeline roche annual report pharmapipelinefusszeilenengindd page noitacidni tcudorptcejorp di tcejorp recnac revil bamuzutrano gr sruomut dilos bam reh gr sruomut dilos bam rfsc gr sruomut dilos hni kem gr ygolocno bam fgevgna gr sruomut dilos hni laud kem far gr sruomut meh dilo tna mdm gr amonalem faroblez bam ldp gr sruomut dilos nitsava bam ldp gr sruomut dilos binitemiboc bam ldp gr sruomut dilos bam ldp gr recnac etatsorp cda paet gr citaercnap recnac nairavo cda cum gr amoleym elpitlum cda gr ygolocno cda bipan gr ygolocno cda gr llc avyzag hni lcb gr snoitacidni meh hni lcb gr amohpmyl sruomut dilos hni khc gr sruomut dilos hni kip gr amonalem citatsatem cda rbte gr enil dn amotsalboilg hni kip gr sruomut dilos ci vli aec gr sruomut dilos gr sruomut meh gr sruomut dilos hni kip uhc enil dn cbm reh atejrep gr lma egdevire gr ccb elbarepo egdevire gr enil ts crcm bamuzutrano gr enil ts suomauqs non clcsn bamuzutrano gr enil ts suomauqs clcsn bamuzutrano gr sruomut dilos hni kip bisilitcip gr sruomut dilos hni tka bitresatapi gr enil rdn clcsn bam ldp gr ccr nitsava bam ldp gr sruomut meh cda dc nitodev bamuzutanip gr sruomut meh cdabdc nitodev bamuzutalop gr sruomut lailehtipe bam rfgereh gr ledp tcarferl llc hni lcb gr clcsn rotibihni kla binitcela gr recnac revil bam nacipylg gr jda cb genreh nitsava gr jda clcsn nitsava gr dionicrac ksirhgih nitsava gr enil ts recnac nairavo nitsava gr evitisnesmunitalp recnac nairavo despal nitsava gr tnerrucer recnac lacivrec nitsava gr cb ylrae reh atejrep gr recnac cirtsag reh atejrep gr recnac cirtsag reh alycdak gr enil ts cbm reh atejrep alycdak gr cb ylrae reh alycdak gr enil rdn clcsn bamuzutrano gr recnac cirtsag bamuzutrano gr tum rfge l clcsn bamuzutrano gr lcbld bamuzutunibo avyzag gr despaler lhni bamuzutunibo avyzag gr eniltnorf lhni bamuzutunibo avyzag gr jda amonalem faroblez gr amonalem faroblez obmoc binitemiboc gr tcarferl llc hni lcb gr noitalumrof cs lhn arehtbam gr tnatsisertp ac nairavo ler nitsava gr enil ts amotsalboilg nitsava gr llc ag bamuzutunibo gr sesaesid enummiotua bam li gr ar bam rli uhc sisorelcs cimetsys armetca gr sisorbfi yranomlup cihtapoidi bamuzikirbel gr sitiloc evitareclu bamuzilorte gr susotamehtyre supul cimetsys bamuzilatnor gr amhtsa bamuziliuq gr sititamre cipota bam rli uhc sitiretra llec tnaig armetca gr amhtsa ereve bamuzikirbel gr ylagemorca editoertco laro gr yhtaposehtne lynevus uhc ar ylrae armetca gr noitalumrof cs ar armetca gr airacitru cihtapoidi cinorhc rialox gr vbh tsinoga rlt gr vbh tsinoga rlt gr vch enibaticirem gr vch riverponad gr vmc gr acneuflni bam aulf gr vch rivuborte gr lairetcabitna citoibitna dtpl gr esaesid yendik gr setebaid epyt oga laud plgpig gr dvcsca bamucalcni gr sesaesid cilobatem bam kscp gr sredrosid evitingoc man aabag gr ainerhpozihc hni aedp gr ainerhpozihc gr yhporta ralucsum lanips recilps nms gr sremiehzla hni boam gr noisserpe man ulgm gr esaesid evislupmoc evissesbo nitrepotib gr noisserpe tnatsisertnemtaert man ulgm gr msitua tsinogatna rotpecer v gr sremiehzla bamuzenerc gr sremiehzla bamurenetnag gr smr bamuzilerco gr smpp bamuzilerco gr smotpmys gen zihcs nitrepotib gr lortnoc tpobus zihcs nitrepotib gr emdovrdma vile tsus sitnecul gr dmaw gr yhporta cihpargoeg rotcaf bamuzilapmal gr ailihpomeh bam cfiicepsib xfaxif uhc fda submission pende rgno roche genentech manage submit eu chu chugai manage submit eu filing pende rg mabthera brand approve submit eu rituxan japan submit rg actemra brand personalise healthcare roactemra eu project acs acute coronary syndrome mab monoclonal antibody amd agerelate macular degeneration mbc metastatic breast cancer bcc basal cell carcinoma nhl nonhodgkin lymphoma cll chronic lymphocytic leukemia nsclc nonsmall cell lung cancer cmv cytomegalovirus ppm primary progressive multiple sclerosis crc colorectal cancer ra rheumatoid arthritis cvd cardiovascular disease rm relapse multiple sclerosis dlbcl diffuse large bcell lymphoma rvo retinal vein occlusion dme diabetic macular edema sc subcutaneous hbv hepatitis b virus td type diabete hcv hepatitis c virus ygolocno noitammalfni ygolonummi suoitcefni sesaesid cilobatem ralucsavoidrac ecneicsoruen ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp ddnigneenilepipamrahpraehcorpharmaceutical pipeline roche annual report pharmaceutical pipeline pharmaceutical pipeline roche annual report pharmapipelinefusszeilenengindd page noitacidni tcudorptcejorp di tcejorp recnac revil bamuzutrano gr sruomut dilos bam reh gr sruomut dilos bam rfsc gr sruomut dilos hni kem gr ygolocno bam fgevgna gr sruomut dilos hni laud kem far gr sruomut meh dilo tna mdm gr amonalem faroblez bam ldp gr sruomut dilos nitsava bam ldp gr sruomut dilos binitemiboc bam ldp gr sruomut dilos bam ldp gr recnac etatsorp cda paet gr citaercnap recnac nairavo cda cum gr amoleym elpitlum cda gr ygolocno cda bipan gr ygolocno cda gr llc avyzag hni lcb gr snoitacidni meh hni lcb gr amohpmyl sruomut dilos hni khc gr sruomut dilos hni kip gr amonalem citatsatem cda rbte gr enil dn amotsalboilg hni kip gr sruomut dilos ci vli aec gr sruomut dilos gr sruomut meh gr sruomut dilos hni kip uhc enil dn cbm reh atejrep gr lma egdevire gr ccb elbarepo egdevire gr enil ts crcm bamuzutrano gr enil ts suomauqs non clcsn bamuzutrano gr enil ts suomauqs clcsn bamuzutrano gr sruomut dilos hni kip bisilitcip gr sruomut dilos hni tka bitresatapi gr enil rdn clcsn bam ldp gr ccr nitsava bam ldp gr sruomut meh cda dc nitodev bamuzutanip gr sruomut meh cdabdc nitodev bamuzutalop gr sruomut lailehtipe bam rfgereh gr ledp tcarferl llc hni lcb gr clcsn rotibihni kla binitcela gr recnac revil bam nacipylg gr jda cb genreh nitsava gr jda clcsn nitsava gr dionicrac ksirhgih nitsava gr enil ts recnac nairavo nitsava gr evitisnesmunitalp recnac nairavo despal nitsava gr tnerrucer recnac lacivrec nitsava gr cb ylrae reh atejrep gr recnac cirtsag reh atejrep gr recnac cirtsag reh alycdak gr enil ts cbm reh atejrep alycdak gr cb ylrae reh alycdak gr enil rdn clcsn bamuzutrano gr recnac cirtsag bamuzutrano gr tum rfge l clcsn bamuzutrano gr lcbld bamuzutunibo avyzag gr despaler lhni bamuzutunibo avyzag gr eniltnorf lhni bamuzutunibo avyzag gr jda amonalem faroblez gr amonalem faroblez obmoc binitemiboc gr tcarferl llc hni lcb gr noitalumrof cs lhn arehtbam gr tnatsisertp ac nairavo ler nitsava gr enil ts amotsalboilg nitsava gr llc ag bamuzutunibo gr sesaesid enummiotua bam li gr ar bam rli uhc sisorelcs cimetsys armetca gr sisorbfi yranomlup cihtapoidi bamuzikirbel gr sitiloc evitareclu bamuzilorte gr susotamehtyre supul cimetsys bamuzilatnor gr amhtsa bamuziliuq gr sititamre cipota bam rli uhc sitiretra llec tnaig armetca gr amhtsa ereve bamuzikirbel gr ylagemorca editoertco laro gr yhtaposehtne lynevus uhc ar ylrae armetca gr noitalumrof cs ar armetca gr airacitru cihtapoidi cinorhc rialox gr vbh tsinoga rlt gr vbh tsinoga rlt gr vch enibaticirem gr vch riverponad gr vmc gr acneuflni bam aulf gr vch rivuborte gr lairetcabitna citoibitna dtpl gr esaesid yendik gr setebaid epyt oga laud plgpig gr dvcsca bamucalcni gr sesaesid cilobatem bam kscp gr sredrosid evitingoc man aabag gr ainerhpozihc hni aedp gr ainerhpozihc gr yhporta ralucsum lanips recilps nms gr sremiehzla hni boam gr noisserpe man ulgm gr esaesid evislupmoc evissesbo nitrepotib gr noisserpe tnatsisertnemtaert man ulgm gr msitua tsinogatna rotpecer v gr sremiehzla bamuzenerc gr sremiehzla bamurenetnag gr smr bamuzilerco gr smpp bamuzilerco gr smotpmys gen zihcs nitrepotib gr lortnoc tpobus zihcs nitrepotib gr emdovrdma vile tsus sitnecul gr dmaw gr yhporta cihpargoeg rotcaf bamuzilapmal gr ailihpomeh bam cfiicepsib xfaxif uhc fda submission pende rgno roche genentech manage submit eu chu chugai manage submit eu filing pende rg mabthera brand approve submit eu rituxan japan submit rg actemra brand personalise healthcare roactemra eu project acs acute coronary syndrome mab monoclonal antibody amd agerelate macular degeneration mbc metastatic breast cancer bcc basal cell carcinoma nhl nonhodgkin lymphoma cll chronic lymphocytic leukemia nsclc nonsmall cell lung cancer cmv cytomegalovirus ppm primary progressive multiple sclerosis crc colorectal cancer ra rheumatoid arthritis cvd cardiovascular disease rm relapse multiple sclerosis dlbcl diffuse large bcell lymphoma rvo retinal vein occlusion dme diabetic macular edema sc subcutaneous hbv hepatitis b virus td type diabete hcv hepatitis c virus ygolocno noitammalfni ygolonummi suoitcefni sesaesid cilobatem ralucsavoidrac ecneicsoruen ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp ddnigneenilepipamrahpraehcorpharmaceutical division major clinical trial product indication trial phase outcome aleglitazar metabolic disease alecardio independent datum safety monitoring board dsmb phase iii recommend trial halt safety signal lack efficacy avastin advanced cervical gog study meet primary endpoint improve overall survival cancer phase iii statistically significant reduction risk death woman receive avastin plus chemotherapy compare receive chemotherapy avastin metastatic nonsmall people receive avastin plus chemotherapy benefit cell lung cancer phase iii significant improvement progressionfree survival compare line china receive placebo plus chemotherapy etrolizumab moderatetoseverely eucalyptus study meet primary endpoint clinical remission show active ulcerative colitis phase ii tolerate clinically significant safety concern gazyva chronic lymphocytic cll stage gazyva plus chlorambucil improve overall survival leukemia phase iii compare chlorambucil stage gazyva plus chlorambucil significantly reduce risk disease worsen death compare mabthera rituxan plus chlorambucil people previously untreated chronic lymphocytic leukemia kadcyla herpositive thresa kadcyla significantly extend time people advance metastatic phase iii herpositive breast cancer live disease worsen breast cancer compare people receive treatment physician choice openlabel study lampalizumab advanced dry macular mahalo study meet primary endpoint change area geo degeneration eye phase ii graphic atrophy patient advance form dry age geographic atrophy relate macular degeneration amd strong treatment effect observe patient positive complement factor cfi genetic biomarker tarceva nonsmall cell lung radiant study meet primary endpoint improve diseasefree cancer phase iii survival dfs tarceva improvement dfs adjuvant treatment patient surgicallyresecte nsclc compare placebo xolair chronic idiopathic asteria ii xolair meet primary endpoint patient moderate severe urticaria phase iii chronic idiopathic urticaria remain symptomatic despite glacial treatment approve h antihistamine dose phase iii pharmaceutical division major regulatory filing product clinical datum support filing indication dosage form country actemra function phase iii early rheumatoid arthritis eu alectinib japanese phase iii study alkfusion genepositive unresectable recurrent japan japiccti advanced nonsmall cell lung cancer avastin aurelia phase iii platinumresistant ovarian cancer eu avastin avaglio phase iii glioblastoma eu avastin metastatic nonsmall cell lung cancer line china gazyva cll phase iii chronic lymphocytic leukemia obinutuzumab cll phase iii chronic lymphocytic leukemia eu xolair asteria ii phase iii chronic idiopathic urticaria roche annual report research developmentpharmaceutical division major regulatory approval product clinical datum support filing indication dosage form country actemra summacta phase iii brevacta rheumatoid arthritis ubcutaneous phase iii actemra summacta phase iii brevacta rheumatoid arthritis japan ubcutaneous phase iii musashi phase iii matsuri phase iii actemra cherish phase iii polyarticular juvenile idiopathic arthritis eu roactemra avastin ml phase iii metastatic colorectal cancer tml treatment multiple line avastin brain phase ii jo phase ii newly diagnose relapse glioblastoma japan avaglio phase iii avastin gog phase iii icon phase iii ovarian cancer japan erivedge erivance bcc phase ii advanced basal cell carcinoma eu conditional approval herceptin hannah phase iii prefher phase ii herpositive breast cancer eu ubcutaneous gazyva cll phase iii chronic lymphocytic leukemia line kadcyla emilia phase iii herpositive metastatic breast cancer eu second later line japan lucentis harbor phase iii inclusion frequent dose regimen wet agerelate macular degeneration mabthera rave phase iii active gpa mpa type eu rituxan ancaassociate vasculitis pegasys ped c phase iii chronic hepatitis c child year eu age old perjeta cleopatra phase iii herpositive metastatic breast cancer eu japan line perjeta neosphere phase ii herpositive breast cancer neoadjuvant accelerate approval tarceva eurtac phase iii egfrmutationpositive nonsmall cell lung cancer line research development roche annual report roche diagnostic test personalise treatment market late development disease area disease drug diagnostic test technology application virology cmv valcyte cmv viral load pcr monitor hbv pegasys hbv viral load pcr monitoring antiviral hbv pegasys peginterferon hbsag levels immunoassay monitor alfab mercksp hcv pegasys peginterferon hcv viral load pcr monitor alfab mercksp hcv mericitabine r hcv viral load pcr monitor hcv danoprevir rg hcv viral load pcr monitor hiv antiviral hiv viral load pcr monitor hiv abacavir glaxosmithkline hlab genotype pcr screen oncology breast cancer herceptin kadcyla perjeta expression ihc ish selection gene amplification breast cancer tamoxifen erpr expression ihc selection hormonal therapie cancer compound merck p mutations microarray selection colon cancer cetuximab merck kras mutation pcr selection panitumumab amgen gastric cancer herceptin expression ihc ish selection gene amplification lymphoma brentuximab vedotin cd expression ihc selection seattle geneticsmillennium melanoma zelboraf cobimetinib rg braf mutation pcr selection nsclc tarceva egfr mutations pcr selection gefitinib astrazeneca nsclc onartuzumab meet expression ihc selection metmab rg nsclc antipdl rg pdl expression ihc selection nsclc tg transgene muc expression ihc selection inflammation asthma lebrikizumab rg serum periostin immunoassay selection level rheumatoid arthritis mabtherarituxan rf anticcp ab immunoassay selection ophthalmology geographic atrophy lampalizumab cfiexpression pcr selection neuroscience alzheimer disease gantenerumabrg level immunoassay selection project pharmaceutical company disclose confidentiality reason available market selection patient eligible firstline treatment black type market grey type development monitor monitor patient response particular treatment screening screen patient particular genetic variation hlaassociate hypersensitivity abacavir selection selection patient eligible particular treatment anticcp ab antibodie cyclic citrullinate peptide braf bisoform rapidly grow fibrosarcoma oncogene cfi complement factor cmv cytomegalovirus egfr epidermal growth factor receptor erpr estrogen receptorprogesterone receptor hbv hepatitis b virus hbsag hbv surface antigen hcv hepatitis c virus human epidermal growth factor receptor hiv human immunodeficiency virus hla human leucocyte antigen ihc immunohistochemistry ish situ hybridisation kras member ras family oncogene meet methioin muc member mucin glycoprotein family pcr polymerase chain reaction rf rheumatoid factor sp scheringplough roche annual report research developmentdiagnostic division major product launch area product description market instrumentsdevice laboratorie cobas nextgeneration modular preanalytic eu diabetes care accuchek active test strip accuchek active test strip ww maltoseindependent chemistry exclude na life science gs flx long amplicon software longread target sequence ww testsassay oncology calcitonin test medullary thyroid cancer eu progrp test small cell lung cancer eu cobas egfr test nonsmall cell lung cancer stratification er primary antibody ivd immunohistochemistry test determine state hormone receptor breast cancer tissue cintec plus cytology cervical precancer test eu infectious disease capctm hcv nextgeneration hcv viral load test transplantation elecsys cyclosporine immunosuppressive drug monitoring eu tacrolimus test sequence seqcap ez reagent kit singlesource reagent kit ww diagnostic division key product launch plan area product description market instrumentsdevice laboratorie cobas generation molecular pcr system ww cobas fully integrate automate hematology system eu cobas automate urinalysis work area eu connectv middleware provide connectivity lis ww diabetes care accuchek insight generation insulin pump bgm system eu accuchek connect bg meter connectivity smartphone eu mobile app cloud testsassay blood screen mpx generation blood screen multiplex test infectious disease mpx hiv hcv hbv hev nat blood screening menu cobas ww dpx wnv hiv hcv hbv virology test cobas ww hsv detection herpe simplex virus cobas eu syphillis immunoassay detection treponema pallidum eu microbiology mrsasa generation test cobas eu cdifficile diagnosis clostridium infection eu womens health amh assessment ovarian reserve fertility eu pe prognosis claim extension shortterm prediction eu preeclampsia pregnancy exclude hospital information system blood glucose monitor parvovirus b hepatitis virus west nile virus research development roche annual report help fight hepatitis b roche business report make innovation accessiblechina million people chronically infect hepatitis b virus hbv worldwide million live china hbv main cause chronic liver disease cirrhosis primary liver cancer number patient chronic hbv infection treat pegasy bring stateoftheart therapy patient people hepatitis unaware infection simply access treatment china order help situation roche establish diagnostic capacity medical training improve knowhow wide access correct treatment regime pharmaceutical diagnostic division work closely ensure right treatment offer right patient give preva lence hepatitis b china vital identify patient subgroup likely benefit target therapy result patient improved outcome integrate approach mean patient quality life enormously improve resource optimally make innovation accessible roche annual report manufacture site roche annual report manufacturing procurement approve million swiss franc investment biologic production capacity enable rapid launch kadcyla gazyva conduct sustainability audits supplier high level compliance confirm roche annual report manufacture procurement key figure manufacture site pharmaceutical diagnostic joint site portfolio medicine reagent kit instrument manufacture procurement supply function contin medicine roche pipeline equipment refur ued support rapid development new roche medicine bishment diagnostic test priority review status breakthrough basel switzerland million swiss franc therapy designation new product like kadcyla build antibodydrug conjugate adc production facility gazyva represent important recognition provide additional capacity flexibility breakthrough medicine result shorten vacaville oceanside united states mil timeline launch similarly set ambitious time lion swiss franc increase biologic manufacturing line launch new diagnostic product pacitie include commission previously idle cobas system internally mean continuously second bulk drug production unit genentech vacaville shorten timespans launch bring product facility patient customer particularly manufacture supply expect create approximately new job investment launch new product maintain quality supply patient meet demand underlie growth business biologic manufacturing strategy include internal key priority manufacture procurement sup external network help ensure agility flexibility ply operation function support address demand uncertainty supply resiliency addition strong sale growth new exist product en investment internal network biologic able roche strengthen leadership oncology manufacturing strategy include establish strategic biotechnology vitro diagnostic continue focus nership select target reliable external manufacturing supply exist product meet stringent organisation health authority requirement maintain reliable deliv ery customer support area include r pipeline remain priority stream pharmaceutical lining network capital investment support busi ness priority network pharmaceutical manufacturing network produce medicine clinical trial commercial supply investment future world sophisticated biopharmaceuti cal production plant network host approximately year board approve million swiss franc global biologic production capacity make roche larg investment global pharmaceuticals manufacturing est manufacturer biotech sector network investment span year increase production capability biologic medi cine provide strong foundation deliver investiga tional biologic medicine pipeline invest penzberg germany approximately million swiss worldwide mammalian cell culture capacity include contract manufacturing organisation bioplan associates inc annual report franc support delivery investigational biologic internal analysis roche annual report manufacture procurementmanufacture site roche group pharmaceutical mannheim diagnostic penzberg basel kaiseraugst rotkreuz segrate clarecastle hillsboro indianapolis branford south san francisco vacaville branchburg legans utsunomiya tucson florence yokneam illit shanghai fuju iek dim aa oceanside toluca ponce singapore rio de janeiro performance take decision phase production grow number project pipeline require dili operation toluca mexico regular assessment gent planning manufacture network ensure worldwide manufacturing network reveal significant successful commercialisation innovative approach continue underutilisation facility technical development increase rate year reduce production close manufac success facilitate launch kadcyla day ture site approval gazyva working day approval maintain high standard quality patient recognise opportunity challenge pose pharmaceutical pipeline launch project increase capability capacity commercialise new product project currently investigate range aspect include resource planning deployment launch site strategy speeding process involve commercialise new molecule manufacture procurement roche annual report pipeline patient fast datum accelerate approval timeline begin sub mission fda april fda give gazyva breakthrough therapy designation priority review originally gazyva launch schedule june accelerate fda approval process gazyva ga receive fda approval month early obinutuzumab new medicine treat chronic lymphocytic originally expect friday november pharma leukemia underline importance new treatment come ensue challenge work year patient speed approval come signifi manage continuously shorten time period launch day not operational challenge year research gazyva available patient work day approval development phase iii data gazyva available grant authority spring show significant medical benefit positive research early development clinical development commercialisation market phase iii approval process phase iv month originally schedule leadtime application file regulatory approval month research early development clinical development commercialisation market phase iii approval process phase iv month gazyva month fda file april fda approval november diagnostic performance achieve goal save cost maintain network e supply product meet division abovemarket manufacturing network roche diagnostic handle sale growth production logistic industryleade portfolio vitro diagnostic product include stateoftheart deliver million test kit elecsys immuno instruments different reagent kit different assay product line run automate testing system type consumable pipette cuvette billion test conduct kit roche diagnostic offer billion support launch major diagnostic product consumable key market include cobas new cancer test manufacture majority instrument test inhouse allow maintain cost quality advan complete transfer chemical operation mann tag leverage proprietary technology special ex heim germany site penzberg germany con pertise use external manufacturer need access tract manufacturer additionally close burgdorf unique technology control cost example pro switzerland site january transfer operation duction handheld blood glucose meter large work sta mannheim tion consumable increase number sub assembly roche annual report manufacture procurementlocal project increase focus increase local capability believe access healthcare provide sustainable way address health need develop healthcare system future work egyptian government example roche produce pegasys manufacture expert work number country herceptin mabthera locally different trade name second brand initiative product packaging package distribute locally product rebrande version original brand manufacture production site original subject quality control procedure partner local manufacturer endstage manufactur ing second brand help strengthen local manufacturing capability increase local skill provide employment programme range training healthcare profession al helping establish clinic laboratory strength ene local manufacturing capability supply chain continue restructure roche diabetes care capital investment year sustain longterm profitability diabe focused expand capacity m tes care market remain challenge treman prove efficiency manufacture network dous growth opportunity believe posi penzberg germany increase raw material pro tione remain lead provider space mass duction elecsys immunoassay build diagnos production capacity seven billion strip year tic production complex project represent highlevel quality favourable cost structure base investment approximately million swiss franc start inhouse outsource manufacturing march expect complete mannheim germany invest million swiss progress longterm franc additional production capacity support clini initiative include supply chain excellence direct cal chemistry immunochemistry product line include procurement excellence project aim sustainable high new production facility performance include maintain continuous m prove ment culture support metric manufacture quality performance introduction methodolo gy tool ensure robust production process initiate activity adapt distribution process plan network improve customer satisfac tion distribution expense inventory level quality com pliance verify internal audits diagnostic division total manufacturing site successfully manage inspection regulatory authority notify body registrar critical issue identify manufacturing procurement roche annual report start harmonise payment term group reduce trade work capital activity complete supplier day china division continue improve value efficien second supplier day china bring cie year number key activity participant learn sustainability improve organisational structure capability man roche supplier audits follow event supplier age spend improve sustainability standard commit com develop category roadmap strategy spend ply roche supplier code conduct joint diagnostic pharmaceutical category manage work closely roche innovation anticorrup ment teams tion risk management recycling priority area develop longterm category strategy category increase focus sustainability yield roadmap well match pharma business requirement million swiss franc direct benefit past supplier capability year chinese supplier audit continue direct procurement excellence programme complete agree followup diagnostic improve management supplier network risk management deliver result engage supplier believe supplier engagement critical number reason manage performance risk effectively ensure quality compliance reduce combine environmental footprint foster innovation end num ber initiative place strengthen relationship sup plier example roche supplier relationship center south san francisco united states open bring roche procurement staff strategic supplier seek opportunity innovation prod uct development new process recycle risk reduction supplier relationship center deliver result supplier relationship center complete pilot phase manufacturing improvement initiative procurement deliver significant saving roche select partner provide packaging component singleuse technology pro procurement team continue pursue variety duction filter chromatography resin approach strengthen business unit generate contract manufacturing roche product cost saving reinveste business collaborate supplier introduce external phar improve capability meet demand maceutical sector programme increase environmental grow number project pharmaceutical pipeline compliance whilst reduce audit workload centre expand include supplier product develop align building capability ment area procurement roche organise division mirror structure business facilitate high level establish formal supplier relationship management support closely coordinate procurement policy process roche achieve systematic classification sup process system largevolume spend group plier enable focus critical strategic supplier strengthen alignment development result close relationship improve performance groupwide procurement policy implement risk management roche annual report manufacture procurementmonitore compliance tion ability manage quality performance exchange update supplier elearne module good practice network roche supplier code conduct make available language complete supplier supply chain management representative date commitment quality innovation sustainability ex tend supply chain respond quickly close collaboration supplier reflect market development ensure reliable endtoend prod finding supplier audits high level compliance uct supply reduce environmental footprint main roche industry code standard tain highly integrate responsive global supply chain division continue investigate implement conduct sustainability audits supplier enhancement process worldwide compare supplier directly involve supply chain dedicated project involve planning provider good service majority com munity deliver improve streamlined pro audit supplier locate latin america asiapacific cesse major project aim improve work pro eastern europemiddle east terminate business cesse focus stabilise deliver reliability supplier meet minimum standard operation new focus establish technical pro duct prepare improve management taking shape progress sig nificantly intensify collaboration pharma supplier ceutical supply chain initiative psci able access supplier audit report psci addition start provide raw material global rollout anticorruption compliance questionnaire logistic service packaging research service marketing service quality compliance continent override goal ensure person receive country safe roche medicine reliable diagnostic test result culture achieve apply rigorous standard help manufacture medicine roche product manufacture source additionally deliver customer diagnostic tool ensure quality management system conform patient different reagent kit law regulation current norm stan dards cgmp ich iso roche continue global harmonisation en hancement quality management system pharma ceutical division establish new system global standard area quality management risk manage ment preventive corrective action local imple mentation ongoing diagnostic division effort har monise multiple quality system complete yearend harmonisation expect drive compli ance efficiency enhance manufacturing organisa current good manufacturing practice cgmp international confer ence harmonisation technical requirement registration pharmaceutical human use ich international organization standardization iso manufacture procurement roche annual report overcome hurdle improve access treatment roche business report make innovation accessibleegypt million people egypt infected hepatitis c virus additional new infection year represent major threat public health second brand pegferon allow broad access treatment egypt option target medical care right patient enable healthcare provider optimise use resource available second brand increase access care medical benefit affordability treatment significant problem egypt order address roche introduce pegferon second brand hepatitis treatment pegasys medicine brand package locally vial form allow roche sell medicine low price government result increase access treatment country roche complete offer product diagnosis treatment monitoring help maximise medical service patient benefit make innovation accessible roche annual report patient treat roche selling product roche annual report market pilot innovative pricing model europe host oncologist japan discuss advanced cancer therapy support indepth study state cancer care country roche annual report market key figure sale main market usa million chf europe million chf japan million chf e brazil china india mexico russia south korea turkey million chf growth rate constant exchange rate average fullyear roche supply medicine diagnostic test get medicine treat subgroup patient country worldwide healthcare system vary signif test confirm likelihood response icantly country country country significant advantage payer personalise health country sophisticated medicine diagnostic test care know roche core innovation strategy readily available whilst healthcare infrastructure number disease medicine companion limited basic medical care luxury diagnostic test identify subgroup bring great precision treatment well value healthcare recognise disparity different approach payer add personalised healthcare port help break barrier good healthcare folio launch personalise breast cancer medi longterm view market work closely local cine kadcyla perjeta approval health authority healthcare provider develop tarceva companion diagnostic test firstline therapy way bring medicine test patient lung cancer possible aim person need product able access benefit postauthorisation assessment development market increase adoption postlaunch assessment emphasis real life evidence comparative effective medical value ness safety economic impact medicine frequently assessment link reevaluation pricing develop product significantly improve people live reimbursement condition central premise business believe bring innovative product market demonstrate clear roche member tapestry network working group medical value healthcare provider fundamental sus postlaunch value assessment international group tainable success end actively involve con comprise patient clinical expert healthcare provider tribute health technology assessment htas reimbursement agency payer healthcare policy healthcare authority systematically evaluate medical ben maker propose guideline assessment efit medicine diagnostic test relation group publish recommendation effective investment decision framework guide evidence generation new medicine register launch hta personalise healthcare hta continue increasingly sophisticated wide parallel align organisation internally spread country adopt system improve ability engage healthcare policy decision well assess medical economic value medicine tar roche annual report marketsmaker stakeholder evaluation real disease world impact product awareness h c tacu klin gt ao dim versi es se et cs hao llel nu gest ao ndn dys namic different ur oc se es r mit mm oe cnt imp uo tv ce od h ee salth e etlt sh yc er gf nu nc oit healthcare system require significant longterm commitment fully understand need issue give diagnostic tool country decentralise business model em medicine power local management work closely local health care provider determine good customise solution appropriate market condition fundamental market premise bring disease mean patient need combination real medical value patient healthcare provider medicine lead rethink pricing model help ensure people possible access develop personalise reimbursement model medicine test require tailor strategy model allow differentiate value medicine market develop model effective give indication multiple indication individual healthcare system involve provide pricing valuebase pricing additional clin comprehensive array solution range ical economic value treatment affordability programme strengthen local infrastruc ture work group provide effective personalised reimbursement model patient education support programme personalise reimbursement model potential significant value stakeholder speed access innovative pricing model innovative treatment patient reduce financial believe pricing model future away pressure clinician prescribe option enable volumebased approach valuebased pricing well reflect value treatment price determine effectiveness implement kind model need able track medicine treatment progress science bring use product require close collaboration product treat variety indication response healthcare provider support infra treatment different indication vary considera structure share datum impact patient confiden bly approach tackle tiality new pricing model volumeto valuebase pricing today future unitbase pricing personalise reimbursement model reimbursement drive volume therapy reimbursement drive value therapy deliver patient price differentiate indication undifferentiate price vial price differentiate combination price differentiate treatment course market roche annual report roche begin pilot number project exter way differentiate price introduc nal healthcare providers europe assess pricing tion second brand product second brand model practice italy similar system original product commercialise successfully place multiple indication different name come slightly different form pricing introduce number product example vial syringe example expect country direction india roche develop second brand cancer anticipate able expand access drug herceptin mabtherarituxan hepatitis medicine focus value effectiveness medicine pegasys patient patient assistance programme differential pricing recognise patient develop access good healthcare particularly emerge market country afford treatment vary considerably afford insurance able pay treatment fully access stateoftheart private care majority cover individual insurance plan reason roche reliant poorly fund public healthcare system provide patient assistance programme help address disparity pilot number differential underinsured uninsured access medicine pricing model involve reduce price patient united states example genentech access solution pay andor government medi help underinsured uninsured pa cine prescribe public healthcare system tient access appropriate medicine programme make innovation accessible selection project action area progress strengthen diagnostic capability africa technicians train country roche scientific campus johannesburg south africa patent file enforce lowincome country roche file enforce patent develop medicine country support child type diabete tanzania cameroon healthcare professional train child uganda guinea enrol change diabete child programme drc ethiopia partnership novo nordisk world diabete kenya india foundation international society pediatric adolescent diabetes patient assistance programme treat china patient access herceptin programme herpositive breast cancer roche donate half treatment training lab technician test asia healthcare professional train country awareness campaign hepatitis c testing brazil test administer patient promote early diagnosis receive treatment result second brand key medicine egypt ukraine patient treat second brand available low cost india p akistan collaboration insurance provider china policy sell project begin develop health policy cover cancer help uninsured underinsure patient support genentech access patient access roche product solution mobile mammography unit screen algeria morocco screen programme begin woman rural area north africa tunisia breast cancer team medical educator travel saudi arabia project outreach screen woman breast cancer remote area raise awareness cancer organise symposium doctor improve screen cancer diagnosis roche annual report marketsunderstande roche integrating insight report dialogue challenge cancer care cancer expert policy maker potential partner find solution oncology care challenge highlight develop world high income country year global cancer burden double international forum hold uicc world set double increase cancer leader summit cape town south africa expect come low middleincome country facilitate discussion wide range stakeholder access care severely limited comprehensive work affect change discussion help publicprivate partnership need order formulate idea strategy improve access cancer care progress necessary address situation world conclusion state oncology report professor peter boyle epidemiologist president international prevention research institute multidisciplinary group expert report take nearly year research complete fund roche unrestricted educational grant ensure finding completely independent look detail oncology care country region call urgent action government pharmaceutical industry society come improve oncology care education healthcare involve work collaboration payer nonprofit organisation deliver free medicine patient professional access treatment continue treatment complete course key area activity market support strengthen infrastructure education healthcare professional believe area world healthcare infrastructure rudi understand medical practitioner prod mentary significant challenge exist lim uct current thinking way treat ited fiscal constraint basic level disease well treatment patient facili critical shortage medical professional health facility tate produce broad range educational training low awareness cause symptom prevention material host support medical congress treatment disease poor electricity supply event roche commit provide medical educa hospital equipment run help resolve issue tion new therapeutic area significant unmet roche collaborate local stakeholder government need example schizophrenia par international health organisation support education ticularly active support education bring development healthcare infrastructure improve expertise disease availability medicine provide diagnostic test market roche annual report education healthcare professional selection example area activity improve understand new emerge clinical datum european cancer congress american society clinical oncology improve understanding advance treatment th international transplant infectious disease conference austria diagnosis summer school parkinson disease united kingdom european restless leg syndrome study group annual meeting germany innovation meet portugal training doctor nurse healthcare provider online classroom training session treatment option safety concern product use pediatric cystic fibrosis quality control support patient key roche initiative bring family patient group country asia singapore day training workshop roche event kind region aim event educate group roche sell medicine test effective public policy arena believe critically important provide support provide good practice example part world patient family work closely basis develop idea relevant region patient group clinical trial phase deepen understand impact medicine patient interaction patient believe transpar support patient group effort change pub ency essential publicly declare patient group lic policy provide grant bring key relationship activity rochecom disclose opinion leader policy maker psychiatrist patient group financial nonfinancial support recommend healthcare provider key recommendation european federation pharmaceutical industry asso public policy schizophrenia year ciation efpia host roundtable summit south america bring gether patient group government clinician address believe healthcare education awareness challenge access cancer care region important patient wellbee proper medical develop roadmap policy change year diagnosis treatment end run programme improve situation support patient include counselling service screen support patient family selection example patient support initiative example purpose cancer personally international series roundtable event publication key stakeholder oncology innovation initiative include patient group policy maker patient advocate doctor payer public policy broaden access cancer care international working group roundtable event new york usa patient advocate group policy maker social inclusion academia medical professional look way improve social inclusion schizophrenia patient people affect schizophrenia wwwaccuchekconnectcom tool resource live diabete clinical evidence case study healthcare professional wwwkadcylacom support patient take kadcyla breast cancer roche annual report marketsprogramme website medication remind telephone help line access medical professional advise live disease handle effect treatment improve cancer patient group academy send patient group treatment japan leader annual meeting international experience exchange patient organization sponsor roche request attendee meet help improve cancer treatment japan chugai member academy establish japan experience exchange patient roche group establish chugai academy ad organization develop support project vance oncology chaao fully independent nonprofit organisation improve access good practice oncology doctor researcher patient group doctor researcher academy organise annual conference exchange late development cancer ther apy japans oncologist attend hear worldclass expert advanced cancer therapy research academy publish conference proceeding cost support organise symposia local commu nities unable attend annual conference market roche annual report work healthcare budget roche business report make innovation accessibleeurope personalise reimbursement model future patient p che infrastructure h rm increase ro ret qo n u c ira esp h dt u drr aee ta sic ct oa llk ae bh oo rl ad te ior n v pra il cu ie n gbased r eyap naicinilc develop personalise reimbursement model europe roche working develop personalise reimbursement model reflect value treatment bring patient pilot project run number country pricing volume valuebase pricing reimburse ment vary depend indication combination medicine approach early stage datum system analytic system develop believe enormous potential patient healthcare industry make innovation accessible roche annual report swiss franc support patient organisation roche annual report responsible business strengthen compliance new working model pharmaceutical increase transparency new clinical trial datum share policy define new materiality process roche annual report responsible business key figure contribution healthcare institution million chf contribution patient organisation million chf roche demand high standard ethic integrity division support medical compliance office employee business partner commit ensure integrate align coordinate medical ment responsible business behaviour go strict compliance strategy furthermore reinforce system legal compliance form basis sustainable business monitor provide global oversight medical affair ability create longterm value stakeholder standard medical compliance affiliate roche group know affiliate passport provide metric evaluate activity local safety regulatory medical affair act highlevel issue identification strengthen compliance benchmarke tool focus heavily strengthen compliance confident measure reinforce internal particular external relation stakeholder open structure support aim ensure product dialogue discussion important critical good possible result patient ensure dealing external stakeholder con ducte high standard integrity code conduct issue new directive integrity spec increase regulatory focus profe ify clarify expectation outline roche group sional compliant conduct scientific collaboration code conduct focus area interaction medical practitioner particular response bribery grant advantage take decision implement new work gift entertainment ing model pharmaceutical organisation deal business partner define medical commercial accountability model conflict interest clearly differentiate nonpromotional activity medical scientific nature intent lead account aim sure ambiguity guide ability medical affair promotional activity com line clear employee topic recognise mercial marketing intent conduct leadership lead loss business case commercial team new model implement convince integrity fundamental country activity personnel bud sustainability success business employee get reallocate medical commercial imple require complete training new directive mentation complete end affiliate middle addition training employee operate new model receive code conduct addition strengthen global oversight launch new roche group code con medical compliance global function affiliate duct help advice line employee email seek roche group ensure uniform standard worldwide help advice area uncertainty establish medical compliance committee chair interpret code aim foster culture chief medical officer governance oversight openness ask question order help prevent behaviour body medical compliance good clinical practice breach code serve platform good pharmacovigilance practice pharmaceutical idea suggestion externally advice service roche annual report responsible businessfor business partner contact roche help patient confidentiality commercially sensitive infor advice report noncompliant situation mation protect view highquality analysis clinical trial datum scientific researcher broaden code conduct adhere operate knowledge medicine benefit patient include place local law stringent public health expect business partner comply integrity standard supplier code conduct rochere healthcare institution patient group late business transaction roche chief compliance area commit provide great officer primary contact external stakeholder transparency donation healthcare professional institution patient organisation believe perceive actual breach code important work closely healthcare professional conduct line management local compliance officer patient group area particular expertise chief compliance officer serve contact handle provide support education fund kind issue alternatively employee report noncompliance activity range seminar professional well issue anonymously roche speakup line understand new medical datum sponsor workshop accessible country language educational seminar patient group tolerate retaliation employee raise start consolidate fund directly healthcare compliance concern good faith receive professional event medical congress notification allege violation code conduct line commitment sunshine act expect speakup line report end march chief compliance officer receive estab public policy lishe channel business ethic report area roche active consulting government industry fraud theft violation good marketing practice conflict body regulatory authority stakeholder interest discrimination harassment allegation think tank academic institution help shape debate carefully investigate result termination develop effective law regulation policy public employment contract account unethical behaviour health key area discussion eu agreement business partner reason new law policy relate clinical trial personalise healthcare regulation medical device vitro diagnostic test critical roche business eu consultation pharmaceutical industry increase transparency number issue include data protection falsify medicine pharmaceutical environment roche believe transparency critical pro influence policy membership industry body ductive responsible business environment national regional international level focus clinical trial datum sharing aim forefront industry standard clinical trial result united states genentech actively monitor shaping report rochetrialscom clinicaltrialsgov react public policy debate affect industry publish journal congresse state federal level government landscape new policy expand new policy heavily influence implementation health provide access global clinical study report request care reform continue debate january researcher receive access debt crisis genentech work closely stake patient level datum global clinical trial holder industry body ally influence request review independent panel debate key issue insurance coverage expan expert access give independent panel sion biosimilar drug safety security corporate tax basis good scientific merit patient level datum payment delivery reform anonymise respect privacy patient participate trial line relevant law regulation employee work government official expect follow good practice guideline act appropri expansion policy global commitment increa eat ethical professional manner ing transparency clinical trial information ensure responsible business roche annual report association political institution nonfinancial report roche remain independent political affiliation roche commit triple line principle drive social environmental performance switzerland spend million swiss diligence financial performance franc include payment interpharma economie report perspective guideline evolve inte suisse scienceindustrie swissholding cham grate report fully commit kind ber commerce financial assistance trade union integrate thinking internally assess donation political party cantonal federal level good approach appropriate communication donation political party lowdoubledigit channel roche stakeholder base sess thousand franc sum overall total contri ment decide voluntary global bution donation report initiative g standard order enhance social reporting engagement employee united states personal politi cal contribution roche good government commit particular aspect new guideline materiality assess tee genentech political action committee genenpac ment analysis area relevance potential oppor voluntary political action committee employ tunity risk ability preserve create ee donate dollar political campaign value short medium long term apply committee materiality framework safety security health environment management actively assess impact include financial sustainability initiative contribution healthcare institution business chapter total million swiss franc report company process implement broad materiality assessment education healthcare professional process effectively systemise exist analysis education general public opportunity stakeholder feedback risk believe material roche research formal materiality exercise begin internally roche corporate sustainability committee network key corporate responsibility material topic contribution patient organisation identify provide basis begin full total million swiss franc materiality assessment stakeholder access healthcare educational grant compliance corporate governance workshop seminar meeting ecoefficiency leadership employee engagement treatment adherence project safety product plant supply chain partner disease awareness general education information area find rele vant section report market corporate governance people roche annual report responsible businessthe roche materiality process universe trend issue healthcare sector business relate long list materiality criterion short list revenue increase universe potential issue criterion assess materiality strategic material issue consider issue internal roche deal risk management external stakeholder strategic prioritisation reputation materiality driver business impact stakeholder expectation concern ability influence opportunity differentiation manage risk crisis service group bcm policy guideline place facilitate consistent align local implementation place risk management policy set currently roll new bcm framework approach identify managing report internal group sure roche operation resilient external risk use stakeholder feedback help capable effectively respond major disruption manage social environmental economic risk sustainability risk consistent methodology process routinely roche adopt new business sustainability risk perform risk assessment level organisation assessment approach order ensure emerge social group risk report cover material risk annually environmental economic risk overlook busi discuss corporate executive committee ness sustainability risk include risk affect multiple part audit committee board director regularly company risk longerterm impact date risk management process raise awareness understand risk roche group approach allow assess emerge risk annual basis integrate exist group risk group risk management team provide advisory service management process approach potential business site affiliate project product team monitor risk sustainability risk identify literature review risk pattern specialist area social medium security intelligence source workshop corporate sus compliance sustainability elearne programme class tainability committee risk assess room training workshop place improve expert crossfunctional team result short list stand risk help employee manage appropri business sustainability risk integrate ately group risk management process additionally establish incident management team business sustainability risk identify roche group ensure act quickly earthquake basel tokyo south san francisco emergency team regularly rehearse different cri inadequate strategy cloud mhealth mobile device sis scenario alert escalation procedure continue ehealth electronic device social medium strengthen business continuity management bcm cyber attack ensure site respond effectively catastrophic issue response optimise event deliver minimum acceptable level key product severe income disparity responsible business roche annual report safeguard patient safety roche infringe legal obligation relate report adverse event infringement ensure roche product effective safe procedure ongoing ema expect issue establish systematic process design opti report eu commission april mise patient safety lifecycle medicine drug counterfeiting collaborate regulatory agency monitor report counterfeit medicine diagnostic product adverse event experience patient communicate grow global problem counterfeit find product safety activity appropriate audience disease category region world medicine cause effect patient look identical authentic version difficult priority sure therapeutic benefit detect particularly patient main concern patient medicine outweigh risk quality process health safety substandard falsify drug medicine system regularly audit internally inspect mean difference life death patient regulatory authority work closely relevant stakeholder include pro employee require immediately report issue fessional investigator international association national relate safety quality medicine new learn authority help identify withdraw counterfeit medical ing solution place training reporting product market support prosecution adverse event end year require criminal involve addition train local official employee complete training involve public education counterfeit medicine adverse event store global database review pharmaceutical company qualified physician report promptly appropriate enter agreement interpol pharmaceutical regulatory authority require link roche crime programme build work medical product evaluate benefit medicine product counterfeit pharmaceutical crime unit outweigh risk maintain strict product recall programme include training capacity build target procedure ensure withdraw product rapidly enforcement action build awareness issue quality safety problem arise disrupt dismantle organise crime network involve despite safeguard follow internal quality review order effective comprehensive series anticoun end roche identify unreported potential terfeit measure need place include harmonise miss adverse event patient assistance program product serialisation universal use safety feature united states collaboration relevant health goal prevent people harm counterfeit authority retrospective global search conduct medicinal product internally implement internal identify unreported adverse event report com technical anticounterfeiting measure design pack plete safety assessment impact product age labelling product continue work authority system track trace product november european medicines agency ema distribution dispensary announce prac pharmacovigilance risk assess ment committee confirm roche assessment addition initiative strengthen medicine base available safety information con internal structure network expert worldwide firm benefitrisk balance medicine share knowledge coordinate response counter impact medicine remain authorised feit case involve roche product allow immedi change treatment advice patient healthcare ately inform relevant health authority potentially professional corrective preventative action result counterfeit product bring attention action health authority inspection take place early plan ensure rapid detection analysis suspect product implement timely coordination reporting authority parallel reinspection authority november result additional finding roche ad dressing ema initiate procedure investigate roche annual report responsible businessbiosimilar biosimilar exact copy innovator biological product unlike generic chemically synthesise medicine structural complexity product uniqueness biological production process mean biosimilar identical original medi cine present new challenge regulator pharmaceutical industry bio similar monoclonal antibody approve europe non roche medicine discussion underway world biosimilar regulation place health organization agree new convention name biosimilar regulation development reflect nonidentical nature active sub data stance produce independently develop manufacturing process cesse follow guidance issue world health view biosimilar meet rigorous regulatory organization safety efficacy implica quality standard comparable original medicine tion patient end roche work regulator provide knowledge order approval standard appropriately set overall confident strategy innovate expand protect ensure stay ahead biosimilar competi regulatory environment develop globally bio simi tion example launch number new stand lar raise concern differ standard reg ard care cancer include subcutaneous version ulation emerge market example approval pro herceptin kadcyla perjeta gazyva human right roche group employment policy policy safety security health environmental protection roche fully support implement protect respect policy rigorously enforce internally externally remedy approach un human right council ruggie framework equally commit comply un global compact principle universal declaration human right fundamental labour right stipulate international labour organization declaration fun damental principle right work consistent global standard area company support respect human right sphere influence human right embed code conduct actively ensure roche com plicit human right abuse commitment detailed code conduct supplier code conduct responsible business roche annual report help establish private health insurance cancer roche annual report make innovation accessiblechina number policy sell cover cancer treatment cancer killer urban area china second leading cause death china course cancer medicine cost time average chinese worker annual income work insurer develop coverage cancer chinese population health insurance policy cover cost cancer treatment roche team local insurance company include large help develop additional policy cover cancer treatment care seminar client forum cancer awareness campaign run roche help educate insurer wide population cancer treat make innovation accessible roche annual report employee worldwide roche annual report people reach quartile good employer employee engage launch global wellbeing week activity roche site reach goal woman key position year ahead schedule roche annual report people key figure women key position reach goal year early roche employee worldwide fulltime equivalentsfte employee fte function europe marketing distribution north america research development asia manufacturing logistics latin america servicing australia general administration africa total total employee fte operating unit employee contract type roche pharmaceutical regular fte chugai fix term fte diagnostic division time headcount time headcount total fulltime equivalent fte reflect actual working time parttime employee example parttime employee work result equivalent fte versus employee headcount number fte increase primarily result growth pharmaceutical business asiapacific introduction potential people fundamental inno vationdriven culture purpose roche believe employee mark patient need difference hire outstanding people help manage career recognise reward excellent work aim provide people manager prioritie great leader thing whilst embrace diversity inclusion living value integrity performance courage passion activity create great place work strategic priority focus key area person feels value respected grow engagement diversity inclusion leadership talent attraction retention roche define key position position corporate operating group level key position performance roche annual report peoplepriority aim performance engagement global achieve employee engagement employee engagement score percentage point employee level globally end exceed industry benchmark reach survey quartile good employer health foster culture health launch global wellbeing week activity site wellbee wellb ee worldwide diversity inclusion diverse key position end key position hold woman inclusive hold woman succession pipeline key position woman workplace promote diversity inclusion nationality represent international assignment tolerance discriminative behaviour international assignee woman offer flexible benefit work attendee global leadership programme woman arrangement meet diverse roche employee satisfied benefit exceed need employee industry benchmark benefit close good employer benchmark roche affiliate offer flexible benefit eld care new benefit programme pilot basel site roche affiliate offer flexible working hour offer parttime work arrangement offer work home leadership great leader shape common global leadership roche leadership commitment performance expectation culture unique roche communicate organisation integrate relevant hr practice development planning programme tool include degree feedback talent management performance management talent attraction retention attract ensure robust pool qualified internal key position vacancy fill internally retain candidate critical position international assignment emerge market good talent build pipeline key external talent career development portal job board launch globally align business need increase training hour employee compare late technology method develop employee level performance drive culture create foster culture continuous employee report performance feedback performance performance feedback dialogue line manager improve new compensation drive culture embed new globally align performance management principle introduce compensation performance employee manager feel change management principle principle right thing respond geo survey employee manage measurable target base indicate employee recognition multidimensional performance appraisal improve pilot rollout plan applause global recognition programme complete place globally january range optimal employee engagement level corporation begin benchmark good employer accord methodology aon hewitt global hr consultancy source aon hewitt source hr benefit hb diversity internal survey total roche affiliate participate survey people roche annual report engagement employee geographic region people drive business understanding matter europe people make work roche reward australia engage experience critical success people africa latin america measure employee engagement primarily global employee opinion survey geo objective asia end reach employee engagement level north america global benchmark good employer industry good progress goal survey employer choice recent survey place employee engagement roche consistently recognise employer significant increase choice employee external institution publi put ahead industry global benchmark cation recognition reflect effort create strong optimal employee engagement employer brand differentiate roche competition attest commitment help employee build career survey take feedback collaborative work environment seriously initiate activity address shortcoming ensure maintain positive feature example health wellbeing work groupwide improvement global initiative live find balance launch percentage employee felt value listen september wellbeing week site senior leader see percentage point worldwide participate programme aim fos improvement employee perception career opportunity ter culture health wellbee roche employ clear indication progress rate ee promote worklife balance employee participation compare continue clear understand programme focus theme healthy lifestyle pre employee think feel work roche vention practice emotional wellbeing resource avail able roche site offer range health conduct engagement survey september wellbee information activity service year include employee assistance programme health check include vaccination immunisation fitness nutrition programme stress management interna global employee opinion survey geo tional sos assistance result diversity embrace diversity enrich decision discussion roche bring innovative solution business facet diversity important gender race culture diversity think participation engagement experience believe creativity decisionmake problemsolv ing drive ultimately well different range optimal employee engagement level corporation conflict approach perspective experi begin benchmark good employer accord methodology aonhewitt global hr consultancy roche annual report peopleworldwide recognition roche award roche site fortune good company work roche diagnostic indianapoli fortune good company work genentech crf institute employer china roche diagnostic china crf institute employer switzerland roche switzerland crf institute employer uk roche uk star employer germany praktikantenspiegel roche pharma germany great place work greece roche hellas great place work denmark roche denmark great place work colombia roche colombia desire employer roche diagnostic poland science employer genentech roche russia good employer aon hewitt roche russia lithuania good employer aon hewitt roche lithuania slovakia good employer aon hewitt roche slovakia romania good employer aon hewitt roche romania ence promote inclusive environment individu provide target development opportunity includ al exchange idea opinion openly respectfully e mentor sponsorship programme participation leadership network example regularly sponsor today employee woman worldwide woman science woman leadership forum employee represent different nationality large site basel south san francisco indianapolis represent headquarters site basel mannheim gender diversity support diversity encourage diversity work flexible approach benefit match local programme varied need woman total workforce employee world benefit include sabbatical woman line management parental leave familyfriendly service eg child care sick woman key position child leave flexible work arrangement support gender diversity executive committee effort help employee balance gender diversity continue priority goal work personal commitment line country woman key position sitespecific regulation accommodate company reach goal woman offer possible flexible working hour include key position compare time job sharing opportunity flexible work location arrangement work home share desk work ensure woman fully represent open plan office pipeline internal candidate key position increase percentage woman pipeline global employee survey show employ increase number woman identify ee satisfied benefit percentage point high potential internal talent pool benchmark pharma company line international assignee women overall good employer percentage woman hire roche managerial level increase end woman continue improve benefit programme hold management role site basel united states initiate pilot programme people roche annual report policy address need grow number development employee eldercare responsibility leadership development remain priority roche emphasis people leadership embe equal opportunity de leadership commitment organisation roche equal opportunity employer tolerate commitment introduce site integrate workplace discrimination kind action case relevant hr development practice globally misconduct additionally respect employee right freedom association collective bargaining senior leadership programme catalyst support embed commitment programme aim improve individual collective leadership skill senior leader context adapt business leadership organisational change end target audience senior leader participate programme believe roche employee deserve great leader corporate executive committee member help facil inspire engage team inter itate session action provide employee opportuni tie continuously discover learn develop contribute launch lead leader roche programme globally programme target midlevel sentiment capture leadership commitment leader helping apply leadership commitment develop input authentically conduct pilot pro senior leader response geo commitment gramme fullscale rollout plan provide baseline leadership development programme capture promise employee expect leader challenge conventional participant receive candid feedback london business thinking school adviser roche executive attendance course module horizon programme give leader high potential employee participate horizon programme opportunity challenge conventional thinking experi ence excitement launch new concept participant learn personal responsibility innovation change inspire leader create environment innovation flourish working team leader challenge expand hori zon immediate area responsibility evelope testing hypothesis response critical business chal lenge programme aim improve expertise leader month area strategy management innovation change roche annual report peopledegree feedback medium linkedin twitter facebook youtube important element leadership development pro generate interest career work roche gramme global degree feedback tool encom pass behaviour core competency asso ciate attract employee leadership commitment help leader assess individual strength development target global norm new hire internal staffing rate external staffing rate talent attraction retention retain employee turnover talent strategy pursue recruitment excellence total implement strategy attract outstanding highly europe skilled motivated people help perform consist north america ently high level focus retain employee asia cycle regular development recognition reward tie latin america performance additionally seek continuous supply australia diverse talent qualified help innovate deliver africa business objective recruitment reason leave job vacancy fill internally work continuously identify develop pipeline em ployee candidate key position focus build employeeinitiate external talent pipeline fill gap internal talent pool employerinitiate meet succession management need strong neutral employer brand improve ability attract quality external candidate whilst reduce time hire cost exter nal recruiting agency career development roche aim provide work environment face stiff competition talent science medi employee encourage build career pursue cine especially emerge market india china passion believe career development partnership develop market like san francisco bay area employee manager employee unite states respond challenge drive career role provide right resource global approach include inhouse recruiting team include broad range activity experience role talent scout search potential candidate key posi promote learn growth opportunity tion fill internally recruit senior employee external source key position communicate career development philoso phy launch career development website globally continue attract hire talent traditional specifically pharmaceutical site recruitment practice job posting referral pro development activity provide employee resource grammes recruitment university business school manage career resource help career website country draw million visit employee assess personal interest strength compare million receive identify development need specific career option application post vacancy register new outlined website encourage employee candidate database job seeker interested becom think potential move include lateral cross e roche employee expand use social functional opportunity stretch assignment aim continuous learn people roche annual report training hour employee achievement commitment senior leader regular talent review support global roll succession module chris global hr information solution leadership pipeline number highpotential percentage woman highpotential additionally employee contractor world percentage woman wide online learning solution tool lso com global leadership plete course training include specifically relate programme compliance daily average employee attend instructorle event webbase course com plete performance learn development roche strive performancedriven culture performance management process support continu total training investment ous dialogue feedback aim develop people million chf rewarding performance maximise business result training spend employee chf maintain globally align performance total number training hour management principle reflect approach million compensation matter employee work average training hour recognise reward innovation performance employee teamwork demonstration roche value core number postgraduate competencie interns benefit approach evident pulse check exclude chugai survey complete employee report performance feedback line manager improve believe activity contribute factor new compensation performance management princi percentage point increase employee engagement score ple introduce addition employee career opportunity manager feel change right thing multidimensional performance appraisal process include succession management access online multiinput feedback tool help maintain specific succession plan key collect feedback performance variety source position monitor plan continuously ensure strong diverse pipeline talented candidate recognition recognise employee time effort help result key position vacancy fill retain engage people ensure people feel internal candidate close came value succession plan roche site recognition programme place end maintain succession plan fully support increase number broad organisation position repre global crossfunctional project team address gap senting increase number plan maintain piloted applause recognition programme continue strengthen strategic priority employee south san francisco united states roche annual report peopleremuneration roche connect employee programme purchase roche chf billion security discount show steady progress elev enth year participant additionally manager employee receive award roche long term incentive lti plan lti plan provide partially form restrict stock unit rsus year vest period offer lti recipient competitive package well align value equity hold roche shareholder global product development function plan launch applause site january online pro gramme well support geographically diverse team improve consistency transparency recognition encourage frequent feedback employee employee roche compensation compensation reinforce culture performance play key role attract motivating retain talent compensation principle focus value creation success shar ing fairness transparency balance long short term remuneration affordability market competitive ness spend billion swiss franc remuneration compen sation benefit see great differentia tion reward payment reflect effort integrate payforperformance principle differentiate reward organisation effort helped establish common language tool performance appraisal compensation review organisation improvement compensation performance management facilitate online platform chris affiliates le cercle sirh french association hr information system professional grant chris team hr information system strategy award collaborative solution harmonise hr pro cesse improve hr management worldwide people roche annual report support healthcare system treat cancer roche business report make innovation accessibleperu increase cancer coverage plan esperanza plan hope population cancer coverage plan hope plan hope private militarysocial security public health system sis work government public cancer coverage poor recently public healthcare funding cancer treatment unattainable majority peruvian new government national oncology plan know plan esperanza plan hope set address provide access treatment common cancer time cancer care available general population roche peru support plan educational cancer awareness campaign strengthen diagnostic testing help establish healthcare facility assist medicine pricing make innovation accessible roche annual report employee walk children walk roche annual report community involvement mark year support child need donate supply victim typhoon haiyan launch roche young commission young composer roche annual report community involvement key figure breakdown contribution humanitarian social project science education area art culture community involvement roche employee engage variety community global activity guide roche philanthropic dona philanthropic project enthusiasm idealism tion noncommercial sponsorship policy philanthropic bring discovery development new medicine donation register accredited inde diagnostic product carry involvement social pendent nongovernmental organisation multilateral organi educational humanitarian cultural cause aim sation notforprofit charity active longterm partner enter project early stage share project investment risk employee involvement focus resource select project lasting impact contribution direct distinct area humanitarian social project community envi roche continue enable employee con ronment science education art culture empha tribute skill expertise healthrelate challenge sis place project reflect follow criterion world poor country roche support innovation provide creative effective solution employee spend month work target problem develop country partner organisation sustainability deliver endure result dynamic expertise area roche employee sourceconstraine world temporarily assign project country india collaboration complement work partner organisa haiti kenya tanzania ghana ethiopia niger swaziland tion resource skill togo outcome generate tangible longterm benefit people community involve decade dedication children walk celebrate th anniversary employee basel nutley palo alto site join walk number participant grow steadily reach employee site fund raise match roche roche annual report community involvementhumanitarian engagement malawi social project mark th year involvement malawi start collaborate european coalition positive believe improve service support system people provide hivaids orphan food education effective way build strong healthy skill train participation quickly expand include community develop country investment education roche employee worldwide annual roche children basic health awareness play major role building walk fundraising event help vulnerable child foundation community sustainably majority fund direct long term project malawi hold june coincide south africa roche sponsors transnetphelophepa ser day african child vice bring healthcare education remote communi tie country collaboration transnet addition roche partner unicef build teach foundation philanthropic arm south africas large er train college malawi train teacher stateowne transportation company roche fund mobile possible help reduce number student teacher healthcare clinic know local miracle train include build classroom provide learn service actually car train deliver medical ser terial add previous project conduct unicef vice healthcare education people malawi support school systematic way annually include patient need care transnetphelophepa staff visit school provide primary health check medicine education phelophepa mean good clean health local dialect good neighbour activity describe child participate educational programme brazil programme promote integration young people work environment regular prevention campaign topic hepatitis breast cancer diabete brazil roche expand effort support child family take pro programa vizinho legal good neighbour programme gramme teenager member theatre community jaguar paulo start group perform city country jaguar shanty town close roche affiliate paolo characterise high unemployment relate social problem include high rate teenage pregnancy initially roche employee offer music sport course child school hour activity include violin guitar drum lesson english course theatre dance group soccer programme vizinho legal official rochesponsored programme subsequently expand include school company healthcare institution religious school con gregation join provide room class parent meeting presentation event apart community involvement roche annual report parallel roche philippine consult local authority assess identify short longterm need include way roche contribute philippine recovery recognise young employee local affiliate contribute start scientist fundraise campaign liaise local red cross money raise buy blanket personal hygiene object pack deliver roche hong kong launch young scientist red cross distribution roche separate financial award encourage student age demonstrate donation employee c uriosity passion science develop innovative approach improve people quality life win proposal submit talented yearold hong kong community environment student tactile handwriting word learn kit dyslexic student kit removable sandpaper mesh sheet place smart phone tablet computer screen responsibility majority philanthropic activity enable dyslexic student feel letter lie roche local affiliate operate coun try roche affiliate project support local community approach aim tailor activity effec tively local need united states example genentech give week thousand employee donate money food time nonprofit organisation result real positive change community participation volunteer project donation educational supply clothing food activity science education business found excellence innovation science seek increase public understanding life science inspire future scientist end support programme natural disaster support enhance science education draw talented student science career engage outstanding young scientist roche disaster response model guide contribution teacher community experience unprecedented natural disaster local office able offer immediate roche active supporter swiss youth science response emergency phase disaster long foundation raise awareness appreciation science term support reflect global focus provide sustainable young people national competition study assistance help affect community foot week support swiss talent forum politically independent think tank young adult typhoon haiyan strong storm record expert highprofile personality business science result unprecedented natural disaster medical society politic discuss potential solution global crisis philippine response roche donate supply challenge time highly effective antibiotic bactrim rocephin local stock speed delivery need medicine provide phapcare foundation roche annual report community involvementart culture europe opportunity participate programme activity explore theme creativity innovation roche support contemporary art cultural project synergies arts science student spend actively cultivate artistic talent focus innovative art week salzburg austria participate creative workshop music creative activity express science artistically attend select contemporary classical concert fea explore interaction art science ture salzburg festival programme roche launch roche continents partnership salzburg festival year roche offer student support composer director lucerne festival partner roche commis sions commission work premiere lucerne samy moussa montreal canada piotr festival summer peszat krakow poland composer receive roche young commission compose orchestral work guidance pierre boulez lucerne festival academy programme extension roche commission pioneer collaboration establish roche lucerne festival support contemporary composer innovation art culture roche commission offer contemporary music artist challenge opportunity forge new frontier field start second year recognise contemporary composer select recommendation artistic community involvement roche annual report support people diabete roche business report make innovation accessiblepakistan case diabetes pakistan grow dramatically increase awareness change lifestyle exercise nutrition help people well manage diabetes complication broad access information monitoring tool healthy life roche provide awareness guidance locally good manage diabete avoid complication countrywide education programme support doctor paramedic staff nurse expert advise people live condition session clinic hospital ward programme run month inception make innovation accessible roche annual report percent reduction roche accident rate roche annual report safety security health environment decrease greenhouse gas emission employee reduce heavy metal discharge water way increase share sustainable energy roche annual report safety security health environment key figure energy intensity gjemployee co intensity temployee total environmental impact million impact pointsemployee roche accident rate rar daysemployee include firsttime phosphorus report phosphorus emission base phosphoric acid site genentech production site roche safety security health environmental protection believe education awareness train good integral operation way foster employee engagement responsibility approach level commitment mind conduct regular training session businessrelate activity strive continuous regional conference workshop provide online tool improvement possible economically viable local language employee employee par monitoring performance regularly ensure compliance ticipate approximately hour training standard objective ensure behaviour process equipment stateoftheart audits assessment prevention key effective management policy internally audit critical site chemical devote special attention main tool pro pharmaceutical diagnostic manufacturing facility fessional risk management year relevant site periodically accord risk audits assess performance internal standard stipulate future improvement plant manage ment local officer conduct frequent check improve monitoring inspection assess compliance standard performance expect contract manufacturer supplier service provider meet standard ensure employ people worldwide expert team compliance thirdparty auditor retain period roche site identify risk develop mitigation plan ically inspect operation supplier issue recom communicate policy guideline employee mendation improvement event noncompliance stakeholder motivate implement nec terminate contract refuse renew essary measure audits effectiveness management system review frequently employee encourage identify area improvement recommend change require internal audits database good practice employee frequently followup share knowledge exchange new idea topic time proposal database adopt external audit area organisation followup time coverage key figure aim roche annual report safety security health environmentin follow early audit confirm accident employee year rir correspond improvement interim period recom number working day lose occupational disease mend improvement follow audits include employee year increase involvement line management training level manager improve risk analysis approach aim minimise employee working day lose occupational accident illness actively support employee health safety set realistic goal materiality project aim keep accident minimum establish health safety committee virtually roche assess material issue roche site engage technical activity produc significant positive negative impact company tion laboratory workshop warehouse materiality issue influence external inter site accord risk level nal factor example external regulation law affect strategy stakeholder expectation industry maintain integrate programme employee consulta report convention consider factor tion workplace inspection train business include ability influence issue identify area approach promote strong safety culture importance relevance matter include empower employee report address safety reporting manage actively goal area roche analysis indicate important area employee health safety resource efficiency environment not dummy protection technical asset look main material issue slogan not dummy basel site initiate consider potential future development analyse need local information campaign raise awareness group feasibility act define performance indicator initiate occupational accident goal subject accident project set goal base strategy follow general feature yellow crasht dummy symbolic indicator set priority material issue figure potential accident victim sixmonth period cover chapter team member highlight typical situation dummys occupational accident occupational disease behaviour lead avoidable accident team energy management air emission message consciously avoid accident modify water management use behaviour campaign target employee security include supervisor ensure employee able pharmaceutical environment work optimal health safe condition occupational accident occupational disease employee absenteeism occupational accident occupational disease include unhealthy stress neg ative impact company provide safe healthy workplace employee priority p rimary objective roche accident rate rar reduce reduce roche illness rate rir rar corre spond number work day lose occupational safety security health environment roche annual report issue expect similarly rigorous policy contrac frequency compare resultant number day tor safety employee outside business hour lose increase overall important sell discount protective equip increase work hour rar go ment recreational activity sport equipment rar low level single accident result long absence result performance fluctuation negative trend occupational accident past year intensify accident prevention activity number report case occupational illness de roche accident rate rar show significant creased furthermore related working day decrease workrelate accident decrease lose decline reduce overall roche illness rate low occupational accident illness profile remain con sistent slip fall repetitive strain represent majority workrelate incident sincerely regret roche turkey reduce employee die road traffic accident italy burden environment carry duty employee safety health roche turkey certify world wildlife fund green office programme employee actively take basis step reduce workplace environmental footprint roche accident rate certification pharmaceutical company turkey roche illness rate number total action take achieve green office certi workrelate fication include follow accident optimise staff shuttle bus route reduce driving distance case avoid kilogramme carbon emis workrelate sion year illnesse reduce office paper use save sheet workrelate year fatality eliminate use paper cup annually purchas workrelate ing mug accident remove water dispenser million instal light switch prevent unnecessary lighting work hour plant seedling roche forest esme resource efficiency environment commitment natural resource sustainable manner fundamental roche environmental strategy research manufac ture pharmaceutical diagnostic product dependent natural resource raw material fuel water consequently roche fully aware corporate responsi bility sustainable future commit natural resource efficiently company decrease environmental footprint turn benefit stake roche annual report safety security health environmentholder society reduce greenhouse gas emission ecobalance environmental health problem roche number impact point text benefit economically green technology ser vice transition sustainable energy recycling reduce cost eg energy raw material improve growth competitiveness create employment oppor tunitie aid society additionally roche depend nonrenewable resource vulnerable primary energy supply constraint volatile market price roche generate highvalue product relatively low level energy operation total raw material emission air energy use million swiss franc product sell terajoule compare pharma ceutical company chemical industry apply relatively low co emission commitment sustainable development proactively seek employ new sustainable technolo water gy process minimise environmental impact ecobalance establish groupwide goal ecobalance level allow local site management freedom develop locally appropriate strategy objective reduce environmental impact landfille waste emission water ecobalance refer consumption energy resource emission waste business activity describe total environmental impact environmental impact operation allocate environmental impact point employee million impact point roche product ecologically relevant parameter consumption natural resource emission air water soil obtain view demand place earth eco system point add relate raw material efficiency kg raw material kg total number employee enable monitor product produce improve environmental impact employee million impact point ecoefficiency rate total environmental impact employee slightly decrease ecoefficiency aim minimise ecological damage whilst decrease maximise production efficiency energy materi great big biotech production site vacaville al water decrease hazardous emission product oceanside united states report phos increase recycling use ecoefficiency rate eer phorus emission time base total measure monitor performance eer ratio phosphoric acid site follow period sale expenditure environmental protection environ shutdown mental impact point formula sale expenditure impact point calculate accordance swiss improvement decreasing landfille federal office environment example eer improve waste slight decrease volume withdraw water increase sale increase expenditure environ increase head count positive effect environ mental protection remain constant environmental harm mental impact total use raw material increase reduce safety security health environment roche annual report efficient cool approximately litre fuel oil equivalent carbon emissionfree heating dioxide reduction tonne year datum centre efficiently cool time nearby building resourceefficiently heated end heat pump kw heat output instal roche kaiseraugst switzerland site remove waste heat computer centre use heat water temperature c provide heating office building laboratory building technology provide necessary heating building housing approximately employee represent save energy management ecoefficiency rate eer roche commit minimise environmental footprint sale meaningful way contribute sustainable energy million chf future transform vision reality set energy environmental saving action plan site include implementa expenditure tion innovative technology continuous upgrading million chf infrastructure improve energy efficiency purchase ener environmental gyefficient equipment include hybrid diesel efficient impact car review employee travel need change environmental work process complex task highly regulate impact point approve facility focus effect eer x steady transition use sustainable energy today approximately energy roche come seek improve eer primarily reduce material fossil fuel nonrenewable depleting source energy consumption waste renewable coal oil natural gas result produce green resource eer decrease primarily house gas mainly carbon dioxide waste product increase environmental spending increase contribute climate change air pollution environmental impact point aim use energy efficiently possible reduce addition spend million swiss franc environ energy consumption possible increase use mental purpose investment operating cost sustainable energy continue expand global safety security amount million swiss franc business total spending measure approximately million swiss franc compare energy intensity consumption million swiss franc include increase roche actively reduce energy intensity measure roche increase personnel increase energy employee increasingly energy security measure medical service replacement sustainable source meet energy requirement wastewater treatment plant energy conservation benefit environment avoid air pollution reduce greenhouse gas emission bene roche annual report safety security health environmentfit roche lower cost increase reputational value energy use terajoule efficient use energy ensure business continuity sustainable future generation come goal twofold aim reduce energy intensity gigajoule total energy gj employee level total energy expect reduce energy consumption employee million chf approximately baseline level second sale plan increase proportion sustainable energy total energy total energy consume employee despite strong sale growth manage ensure use resource low possible share sustainable energy increase energy building stationary actual datum goal equipment gas fuel oil waste electricity increase car fuel consumption increase sustainable energy use bring total sustainable energy consumption reduction effort business travel successful energy consumption air travel increase comprise total energy number initiative field compensate negative nonsustainable sustainable impact globalisation increase number employee air emission result overall improvement energy intensity priority avoid air pollutant reduce quantity gj employee absolute energy pollutant control remain pollutant air emission line consumption increase energy consumption ecobalance goal overall objective gj employee surpass goal target emission air low level achieve gj employee recent year way resource management improve emission strategy prescribe continuous improvement demonstrate genentech site san francisco manufacturing site include flue gas scrub usa site participate green building coun ber reduce nitrogen oxides sulphur dioxide vari cil good building challenge commit reduce energy ous incineration freeze process reduce release water waste employee building volatile organic compound voc reduce year take building site energy use halfway point challenge emission air roche site low level energy use type mean new process activity time sampling result fluctuation see natural gas emission air tonne grid electricity district heating voc air travel particulate waste nitrogen oxides sulphur dioxide oil car fleet safety security health environment roche annual report greenhouse gas emission recent acquisition lack alternative coun greenhouse gas ghg emission roche originate try complete elimination halogenate refrigerant transformation use energy goal improve unrealistic continue examine alter energy efficiency apply ghg emission native work refrigeration supplier reduction measure tonne employee reduction aim reduce halogenated refrigerant level expect achieve reduction legacy roche site substitute fossil fuel energy sustainable source recently acquire company genentech ventana cut ghg emission tonne halogenate hydrocarbon tonne employee implement energysaving measure reduce fuel use heat cool operate site inventory emission greenhouse gas emission co equivalent total emission water management million tonne total emission million chf business dependent reliable supply highquality sale tonne water chemical biotech pharmaceutical diag nostics manufacturing process involve water reagent solvent cleaning cool agent pharmaceutical transportation contributor emission industry globally poor quality water result high cost logistic service provider lsp reduce co footprint purification great risk product contamination transportation need know overall emission use water energy carrier refrigeration heating term carbon accounting system provide data installation basis require manage emission develop soft warebase tool calculate intercompany approach direct delivery shipment use standard ensure effective water management roche site lsps certified bureau verita compliant work implement programme reduce water eu iso standard requirement consumption recycle reuse water view water supply use well manage monitor locally shipment mode transportation assess reason site set local target set group single shipment basis allow identify emission wide water quantity target driver focus method emission reduction support global effort promote water initiative reduce greenhouse gas emission protection conservation improve access clean roche reduce use halogenate refrigerant drink water longterm commitment reduce water cool equipment remain atmo consumption reflect goal improve total eco sphere long period time balance compare baseline fur significant progress reduce emission halogenate hydro thermore aim reduce total waste water toxicity carbon eliminate halon reduce fully halogenate baseline meantime continue compound genentech ventana investigate reliable performance indicator measurement site come later reduction programme method establish waste water toxicity baseline later target date half water draw cool circuit water chemically contaminate analyse discharge rest purify treat ment plant release waterway roche annual report safety security health environmentwater trap hillsboro site oregon usa estimate plan water project save approximately cubic metre water annually reduce water consumption land scape soil contain crystal consist super absorbent polymer water crystal trap moisture release soil require crystal plant new vegetation tilled planting bed reduce run irrigation rainfall turn overall cost irrigation performance transfer million cubic metre waste water record organic emission water total organic car treatment plant result discharge tonne bon processing waste water treatment plant organic matter small increase compare favourably discharge waste water pollutant comply fully growth see addition discharge kilo relevant regulation include pretreatment requirement gramme heavy metal leach metal pipe operation waterway approximately elimination rate waste water treatment plant high seek minimise water water contamination water roche commit help protect reduce discharge toxic poorly biodegradable conserve water roche office part world substance heavy metal quality water issue reduce generation waste water important ensure employee provide treat pretreate waste water ozone access clean drinking water case non poorly degradable contaminant roche signatory wash pledge water use discharge access safe water sanitation hygiene implementation workplace movement start ensure appropriate access safe water sanitation water withdraw hygiene employee premise signatory million company control water million waste water discharge pledge start genevabase world business treatment plant council sustainable development provide facility million lead healthy productive employee organic matter discharge waterway treat ment tonne heavy metal discharge waterway treat ment kilogrammes safety security health environment roche annual report waste management security accept responsibility waste generate oper protect employee physical asset critical infor ation include previously deposit site mation integrity brand product prin landfills permit landfilling resort cipal concern roche preventative measure priority inert material slag incineration ash aspect security depend availability suitable local waste treatment plant dispose nonhazardous general waste information security awareness campaign r em authorise landfill ployee started complete r department roche group specialist team consist performance member global department security competitive waste parameter ecobalance intelligence legal brief total employee waste reduction target reflect goal improve different roche site individual sig group ecobalance compare nificantly mitigate risk theft loss businesscritical establish waste reduction goal individual site information set groupwide goal primarily large yeartoyear fluctuation waste construction security activity include launch global demolition activity logistic security programme pharmaceutical division goal systematically improve protection production pharmaceutical diagnostic prod product theft manipulation transportation uct support strong growth roche chemical storage thirdparty warehouse small team lead waste increase general waste decrease global pharma supply chain comprise security expert different site elaborate global guideline tool evaluate mitigate risk report incident user kesslergrube landfill grenzach respect programme roll roche wyhlen germany roche start remediation project site roche affect criminal attack product evaluate remedial option transport hot spot include latin american country production site belleville new jersey usa extensive italy fourphase remediation project underway site nutley new jersey usa schedule completion security focus set north ameri end security workshop hold south san francisco united states site security officer canadian site waste produce tonne discuss challenge good practice key topic region workplace violence logistic security phy ical site protection general waste general waste million chf sale chemical waste chemical waste million chf sale roche annual report safety security health environmentpharmaceutical pharmaceutical environment environment roche acting concern impact pharmaceu tical environment consider entire lifecycle pharmaceutical plant patient drug goal safeguard ecosystem protect business potential longterm finan cial reputational risk trace pharmaceutical product enter environment variety way include manufacturing process waste water treatment plant improper disposal unused medicine natural process follow normal patient use patient use inappropriate generally recognise primary contributor excretion disposal patient evidence suggest exposure result trace concentration surface ground drinking water pose harm human health risk aquatic life think great scientific study identify shortterm effect exposure lowlevel concentration pharmaceutical research conduct public waste water waste treatment plant evaluate potential longterm impact production minimise release pharmaceuti cal environment design manufacturing site reduce risk active ingredient enter waste water product distribute support programme collect expired medicine employ pro natural water system landfill active measure prevent release product environment include offer financial incentive ensure unused date product return retailer supply chain establish policy require return waste pharma drinking water treatment ceutical product incinerate dispose landfill provide environmental risk assessment authoritie new medicine drink water pharmaceutical residue environment come source minor extent estimate emission production site slightly large inadequate disposal unused medicine excretion patient httpenviroadvisorycom pdfpharmaceuticalsintheenvironmentaesgppdf safety security health environment roche annual report make sure access medicine roche business report make innovation accessibleunite state key fact united states universal healthcare system estimate million people united states uninsured product approve genentech donate usd billion worth free medicine patient uninsure deny coverage give uninsured access medicine need genentech access care foundation gatcf establish help patient uninsured deny coverage receive genentech medicine free charge patient meet certain financial medical criterion year gatcf provide support patient united states make innovation accessible roche annual report foundation year ago roche year specialise leader researchfocuse healthcare combine strength pharmaceutical diagnostic roche annual report corporate governance roche commit serve stakeholder basis successful implementation commitment stakeholder corporate governance principle accordingly focus business activity sustainable value creation innovation prescribe management culture conforming recognise standard corporate governance policy transparent communication remuneration report roche success depend ability dedication people recognition form basis performanceoriente remuneration policy system roche annual report corporate governance corporate governance roche commit serve stakeholder basis company article incorporation bylaw successful implementation commitment curriculum vitae member board director corporate governance principle accordingly focus corporate executive committee publish business activity sustainable value creation inno website vation prescribe management culture conforming recognise standard corporate governance policy detail refer follow report transparent communication strong board director represent interest board director shareholder stakeholder highly skilled manager act integrity extremely important th annual general meeting agm roche hold fifth consecutive year roche ltd march shareholders reelect pius baschera recognise dow jones sustainability index djsi paul bulcke william burns christoph franz deanne julius group leader sustainability pharmaceuticals arthur levinson andrea oeri peter r voser beatrice biotechnology life science industry sustainability weder di mauro members board director core business practice award reflect term year provide article incorporation commitment run business way ethical severin schwan elect new member board responsible create longterm value stakeholder director term year provide article incorporation corporate governance report set structure process rule roche take basis organising meeting immediately follow agm function corporate governance roche com board director determine structure compo ply relevant corporate governance requirement sition committee show particular applicable law swiss stock exchange swiss exchange directive include commentary forthcoming annual general meeting march thereto swiss code good practice corporate roche board director propose christoph franz governance promulgate swiss business federation elect chairman board christoph franz economiesuisse company internal governance frame nominate succeed franz b humer announce work particularly article incorporation bylaw annual general meeting march embody principle need ensure com standing reelection addition william burn pany business manage supervise manner decide retire member board director consistent good corporate governance include necessary check balance board director thank member long valuable contribution successful continue develop print annual report contain select link ment roche roche website wwwrochecom reader provide snapshot company report date implement ordinance excessive compensa direct source consult tion list corporation verordnung gegen bermssige time uptodate information corporate governance vergtungen bei brsenkotierten aktiengesellschaften roche annual report cover single financial vegv board director shall propose annual year end december website contain information general meeting schedule march reelect permanent nature late roche news oneyear term member board director stand election annual general meeting elect chairman board director member httpwwwrochecomaboutrochecorporategovernancehtm remuneration committee independent proxy roche annual report corporate governanceinformation relate board director resolve introduce execute time occasion annual general meet corporate governance e march vote remuneration remote electronic ballot mean authorisation instruction independent proxy group structure shareholder mandatory submit annual general roche operate business organise divi meeting resolution amendment sion pharmaceutical diagnostic pharmaceuti article incorporation require vegv cal division comprise business segment roche pharmaceutical chugai genentech segment integrate roche phar maceutical diagnostic division consist follow corporate executive e business area diabetes care molecular diagnos committee tic professional diagnostic tissue diagnostic apply science business area dissolve end portfolio product integrate diagnos effective april john c reed appoint head tic business area roche pharma research early development pre business activity carry group subsidiary member enlarge corporate executive committee associate company detail information roche report severin schwan holding ltd significant subsidiary associate company include company list information information member board director includ domicile share capital equity interest list ing year election member finance report note roche group consolidate corporate execu tive committee list page financial statement subsidiary associate board director corporate executive committee major shareholder list finance report note roche group consolidated financial state ment equity attributable roche shareholder relate party page note financial statement roche holding ltd significant shareholders andr hoffmann vicechairman board director andreas oeri member board director chairman board corporate governance sustain ability committee serve respective capacity board committee representative share holder group pool voting right receive remuneration set forth remuneration report finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive remuneration relationship exist shareholder pool voting right crossshareholding corporate governance roche annual report capital structure board director corporate executive committee information roche capital structure provide information member board director finance report note financial statement roche include year elect year hold ltd additional detail contain term end member article incorporation roche holding ltd corporate executive committee list page change equity detailed finance report note curricula vitae current member financial statement roche holding ltd year body information includ company share capital swiss ing information board membership available franc divide fully pay bearer share continuously update internet nominal value swiss franc restric annual general meeting elect member tion exercise voting right share board director stagger election deposit share vote restriction nominee voted separately article authorise conditional capital incorporation roche holding ltd minute addition nonvoting equity security ne th annual general meeting roche holding ltd hold issue bearer form form march start member board share capital confer voting right ne confer director chairman member remunera right share participate available earn tion committee elect annual general ing liquidation proceed follow repayment meeting annual basis share capital roche ne right pertain exception franz b humer william burn thereto include provision protect interest arthur levinson severin schwan mem nes holder describe article incorpo ber board director member roche ration roche holding ltd corporate executive committee serve executive information debt instrument issue capacity group subsidiary financial outstanding bond provide finance report year precede current reporting period note roche group consolidated financial state internal organisation board director ment debt division authority responsibility board information employee stock option provide management remit board committees finance report note roche group consolidate information control mechanism available financial statement equity compensation plan board dealing corporate management include detailed information stocksettle govern bylaw stock appreciation right ssar plan roche board director roche holding ltd organise restrict stock unit plan roche performance share ensure group conduct business respon plan roche connect roche option plan sibly focus longterm value creation roche issue option apart employee stock end roche board delegate certain responsibility option provide finance report note committee composition chairperson roche group consolidate financial statement equity december describe com compensation plan option issue mittee authority responsibility define detail connection debt instrument bylaw board director option award employee debt instrument issue effect roche share capital httpwwwrochecomaboutrochemanagement boardofdirectorshtm httpwwwrochecomaboutrochemanagement executivecommitteehtm httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance annualgeneralmeetingshtm httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance committeeshtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm articleofincorporationhtm roche annual report corporate governance committee presidium chair nternal audit independent director g roup audit report general counsel direct accord bylaw board director board access give regular briefing audit committee meeting convene chairman present ongoing activity audit report chief request member roche board meet audit risk advisory executive attend audit year assess chairman performance committee meeting external auditor meeting attend chairman chair g roup audit independent appraisal function vicechairman evaluate review group activity service management information system board management annual audit plan yearly define director inform important issue sale focus area eg emerge market thirdparty manage performance etc monthly basis board access ment validate senior management present electronic information platform provide timely audit committee roche group commit information board director board com maintain high standard internal control mittee system control set forth worldwide operation management responsible board director establish system control assess business risk aspect operation continuously monitor audit committee implement effective efficient process corporate governance sustainability committee control whilst ensure compliance internal consist follow element external rule regulation report operate financial risk risk management b conduct operational audits group audit deter system mine management response risk surround r oche system place identify manage business process system evaluate type risk potentially affect business roche appropriateness completeness efficiency pro risk management charter set approach cesse control action plan implement necessary accompany responsibility pharmaceutical change enhancement develop diagnostic division global function conduct businessauditee track completion mal risk assessment process year statutory auditor develop risk plan material risk chief compliance officer compliance officer monitor deviation review regular perfor subsidiary mance dialogue consolidate group risk report safety health environmental protection depart include target risk profile discuss corporate ment executive committee approve corporate sustainability committee group business plan present audit science ethic advisory group seag issue committee process subject regular review relate genetic genetic engineering establish finding present audit committee board member corporate executive committee f details risk management include risk factor invite attend meeting board director risk management charter risk management report person agenda item concern compliance website financial risk management situation warrant member enlarge specifically describe finance report corporate executive committee invite system internal control financial reporting attend board committee invite chairman page finance report board corporate executive committee member deliver report committee meeting elect commission independent expert report service consult ant httpwwwrochecomcorporateresponsibilitybusinessethic riskmanagementandcompliancehtm httpwwwrochecomcorporateresponsibilityenvironmenthtm additional information provide finance report note httpwwwrochecomcorporateresponsibilityhtm roche group consolidate financial statement risk management httpwwwrochecomresearchanddevelopment whowearehowweworkethicsinrdethicalconflictshtm corporate governance roche annual report board board committee attendance corporate governance presidium nomination remuneration audit sustainability board committee committee committee committee number meeting f b humer hoffmann p baschera j bell p bulcke w burns ch franz julius levinson schwan oeri p r voser b weder di mauro member committee invite guest board committee meeting year blackout period impose corporate governance sustainability committee senior employee prohibit trade meeting approx hour company stock follow blackout period effect composition board committee remain december january unchanged march exception mem april april ber board director retire june july board director regularly conduct assessment october october performance blackout period change chairman member corporate executive committee board director circumstance warrant maximum ordinary notice period month board director meet meeting generally management contract fall hour length addition scope subsection annex directive fullday meeting threeday visit major information relate corporate governance subsidiary board committee meet follow presidium board directorsnomination commit remuneration shareholding loan tee meeting approx hour detail remuneration shareholding loan remuneration committee meeting approx set forth separate remuneration report page hour finance report note audit committee meeting approx hour roche group consolidate financial statement equity attributable roche shareholder relate party page list note financial statement roche holding ltd board exec u tive remuneration board executive shareholding page figure indicate actual length meeting include director extensive premeete preparation postmeete followup activity remuneration committee member recuse deliberation decision matter affect interest roche annual report corporate governance participatory right shareholder statutory auditor participate meeting audit participatory right shareholder define committee roche article incorporation roche share issue bearer restriction admission report statutory auditor consolidated finan annual general meeting exception share cial statement financial statement deposit specify period date find page respectively year meeting admittance card issue finance report shareholder provide article incorporation shareholder elect represent kpmg receive follow remuneration service party annual general meeting article statutory auditor roche holding ltd audi incorporation contain restriction exercise vote tor roche company include chugai right quorum requirement stipu late conformity swiss code obligation article incorporation shareholder millions chf represent share nominal value million auditing service swiss franc request placement item auditrelated service agenda annual general meeting accounting service later day date meeting assurance service tax consultancy service change control defensive measure total article incorporation contain provision mandatory bid rule swiss law apply statutory auditor elect year annual changeofcontrol clause component general meeting remuneration base roche ne terminate event acquisition vest period restriction recent year bdo ag serve independent proxy preexisting award remove pay service accord expendi option exercise immediately ture total swiss franc annual general meeting march board director propose relationship statutory auditor election bdo ag independent proxy independent proxy period conclusion ordinary annual general meeting roche holding ltd annual general meeting shareholder march shareholder vote appoint kpmg ag kpmg statutory auditor base exist legal information policy requirement swiss code obligation article provide article incorporation corpo concern maximum term office seven year rate notice publish swiss official gazette auditor charge ian starkey replace predecessor john commerce daily newspaper designate morris auditorincharge start business year board directors basler zeitung finanz und wirtschaft information long auditor auditorin lagefi le temps neue zrcher zeitung charge serve capacity provide roche report halfyear fullyear result business statutory auditor participate audit commit report publish print online format medium tee meeting prepare write oral report event addition detail thirdquarter sale result audits audit committee oversee figure publish year april october assess auditor make recommendation current list publication date available english board information authority responsibilitie german internet audit committee article bylaw httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm articleofincorporationhtm httpwwwrochecommediahtm corporate governance roche annual report relevant information document include medium addition roche establish business ethic release investor update presentation analyst incident report beir system enable chief investor conference available internet compliance officer capture track monitor allege publication order email fax tele violation initial report local compliance officer phone baselwebmasterrochecom resolution business ethic incident tel record system local compliance officer fax receive specific concrete information material contact address investor relation f hoff allege violation roche group code conduct mannla roche ltd investor relation group finance certain predefine category corporate basel switzerland governance sustainability committee audit tel committee board director inform fax substantial violation additional information include detail specific contact chief compliance officer report general person available internet counsel submit regular report corporate governance sustainability committee audit c hief compliance officer committee board director compliance officer network chief compliance officer compliance officer nonapplicabilitynegative disclosure network commit ensure roche group expressly note information contain code conduct consistently comply mention nonapplicable omission roche group serve contact person construe negative declaration provide shareholder employee customer supplier swiss exchange corporate governance directive general public issue relate implementation commentary thereto compliance code employee party aware violation roche group code conduct bring attention manager supervisor report chief com pliance officer ur jaisli direct phone number email ursjaislirochecom disclosure treat confidentially addition end employee anonymously report irregularity complaint mother tongue speakup hotline start december new compliance tool group level call roche group code conduct help advice line introduce strive provide guidance case question uncertaintie interpretation roche group code conduct reference document furthermore serve p latform idea suggestion concern document httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomcorporateresponsibilitybusinessethic codeofconducthtm riskmanagementandcompliancehtm roche annual report corporate governance corporate governance roche annual report remuneration report remuneration report principle remuneration committee track market datum salary roche success depend ability dedication lead global pharmaceutical company report entire people recognition form basis perfor finding board external consulting firm tow manceoriente remuneration policy system er watson assist roche perform market comparison information remuneration committee remit power roche strive create innovative product benefit procedure make remuneration decision patient require outstanding performance find bylaw roche board director employee take continuous innovation help patient outline section principle govern sustain revenue create longterm value innovation specific remuneration component en able pay competitive compensation employ ee distribute rise dividend shareholder dividend increase th year row summary main activity outlook primary aim remuneration policy encourage follow key development decision longterm focus align management interest roche share rise swiss franc swiss interest roche shareholder holder roche franc past year nonvoting equity securities nonvoting equity security nes swiss franc swiss franc roche market value rise line billion swiss franc year remuneration committee roche board billion swiss franc billion swiss franc director meets twice decide remuneration board member member group corporate market value achieve end make roche executive committee base pay bonus stocksettle stock time world ninth large europe valuable appreciation right ssar restrict stock unit rsus enterprise policy decision pension benefit term perfor dividend rise year steadily past year mance share plan psp award decide annually dividend billion swiss franc distribute board director act recommendation remuneration committee past year prove decisive performance share plan price nonvoting equity start total aggregate amount base security increase value share decision submit general meeting lead billion swiss franc rise price approval implement ordinance excessive com company billion swiss franc billion pensation list corporation verordnung gegen ber swiss franc represents increase mssige vergtungen bei brsenkotierten aktiengesellschaf remuneration committee assist consultancy vegv general meeting shall vote annually tower watson regularly track base pay roche bind effect approval remuneration director market datum director pay lead board director resolve board director e global pharmaceutical company major corporate executive committee detail swiss company base remuneration roche direc tor remain unchanged year remain unchanged peer set abbott laboratories abbvie amgen astella astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofiaventis takeda httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm abb credit suisse holcim nestl swiss ubs zurich insurance group actelion nobel biocare sonova straumann synthe roche annual report remuneration report base salary fix pay corporate executive com detail refer follow section mittee cec member remain unchanged remuneration report bonus variable pay cec member financial year consist entirely cash payment case ceo severin schwan reflect sale remuneration policy growth strong growth earning share non roche regularly review policy principle remuner vote equity security development pipeline ation framework employee policy aim stocksettle stock appreciation right ssar vari motivating retain current employee attract tal able ssar grant cec member vest ente new one help roche employee perform year exercise consistently high level remuneration policy design seven year grant date unexercised ssar foster value creation reinforce culture performance lapse compensation fair value innovation apply nonmanagerial employee ssar calculate grant date tri manager nomial model american option detail ssar rsus psp remuneration component restrict stock unit rsus right receive intend align management interest share nonvoting equity security year vest period holder holder nonvoting equity security plus value adjustment equivalent participate manager additional incentive achieve con sum dividend pay vest period attribut tinue value growth form longterm total shareholder able number nonvoting equity security return create value roche investor management individual award grant introduce benefit add value create investor new remuneration component partially replace ssar management penalise receive option value ssar awards reduce balance award form rsus key principle underpin policy company incur additional cost result focus value creation change aim strengthen alignment pay performance management interest interest roche share enable employee share company success holder group longterm success fairness transparency remuneration decision performance share plan psp award variable psp balanced mix long shortterm remuneration com cycle target ne award ponent case psp psp psp market competitiveness psp cycle pay award target ne plan key performance metric total shareholder return tsr calculate threemonth move average constant chf exchange rate remuneration committee decide chief executive officer ceo cec member acquire roche share andor nes equivalent annual base salary ceo annual base salary cec member respectively end retain holding long serve cec addition applicable statutory provision roche long term incentive plan include option partially reclaim distribute compensation result special circum stance clawback detail finance report note roche group consoli date financial statement relate party note financial statement roche holding ltd board executive remuneration board executive shareholding page remuneration report roche annual report remuneration component b bonus base pay bonus block nonvoting equity security bonus award individual contribution value cre nes awards stocksettle stock appreciation right ation mean incentive strive outstanding ssar restrict stock unit rsus performance result create new business opportunity bonus share plan psp support fundamental aim roche amount link group divisional profit sale remuneration policy remuneration component growth operate profit capital charge opac earn link company financial performance commercial ing share ne growth pipeline achieve success align interest roche employee ment measurable qualitative individual functional shareholder performance objective competitive reason roche disclose individual performance objective member explain principle govern remu corporate executive committee neration component report detail amount pay member board director component january follow report year remuneration com chairman board remuneration mittee decide bonus payable chairman remuneration component pay member corpo board member corporate executive commit rate executive committee financial year tee respect current reporting year base perfor mance aforementioned objective annual report submit approval time remuneration committee decide form ordinary annual general meeting bonus award cash payment andor block nonvoting equity security andor block share start board director shall submit separately general meeting bind approval total aggre c stocksettle stock appreciation right ssar gate bonus chairman board director stocksettle stock appreciation right ssar plan corporate executive committee retrospectively introduce january establish uniform system financial year remuneration roche ssar entitle holder benefit financially increase value roche maximum amount total aggregate remuneration nonvoting equity security grant date exclude bonus board director cor exercise date porate execu tive committee period ordi nary general meeting ordinary general meeting ssar award allocate individually remuneration table time general committee discretion meeting prospectively bind approval b restrict stock unit rsus base pay start begin restrict stock unit base pay cash payment determined position rsus right receive nonvoting equity security base salary market datum lead global pharma year vest period plus value adjustment ceutical company footnote reflect individual equivalent sum dividend pay ability experience performance time pay increase vest period attributable number nonvoting equity likewise link individual performance security individual award grant account prevail market condition footnote introduce new remuneration component partially company overall financial situation replace ssar value ssar awards reduce balance award form rsus remuneration committee make review final decision individual base pay pay chairman rsu award allocate individually remuneration board director member corporate executive committee discretion vest recipient committee remuneration member year result nonvoting equity secu board ritie remain block year roche annual report remuneration reporte performance share plan overlap performance cycle psp member corporate executive committee psp psp psp member senior management currently individu close december al worldwide participate performance share plan psp establish period year payment performance share plan determine base threeyear comparison total share board director annual basis act recom holder return tsr peer company footnote mendation remuneration committee f ratio corporate executive committee variable remuneration element bonuse ssarsrsus psp relative fix base pay criterion bonus ssarsrsus psp individual target value assess max ssar consideration performance rsus base annual base pay competitor measure january macroeconomic development year cycle relation value base pay minimum maximum relation value base pay cash payment value development value development block ne determine performance determine performance plus value adjustment start psp dividend ne cycle plus value adjustment grant dividend ne grant performance criterion group objective group individual contribution group performance divisional business remuneration tsr relation performance individual committee decision tsr performance objective consider profit discretion peer set sale growth opac operate profit capital charge earning share ne growth pipeline split group objective na b individual objective na remuneration report roche annual report remuneration board director pursuant switzerland new ordinance excessive corporate executive committee compensation list corporation verordnung gegen ber mssige vergtungen bei brsenkotierten aktiengesellschaften resolution vegv roche commit obtain separate year remuneration committee roche board bind shareholder approval total remuneration pay director decide remuneration board member board director corporate executive com member roche corporate executive committee base mittee describe start agm pay bonus ssar rsus policy decision pension amendment roche article incorporation effect benefit term performance share plan decide vote ordinary agm annually board director act recommenda tion remuneration committee remuneration retrospective approval committee track market datum salary lead total aggregate bonus amount corporate executive global pharmaceutical company footnote report committee chairman board director finding board information committee financial year ended submit retrospectively remit power procedure make remuneration deci ordinary agm separate bind approval sion find bylaw roche board direc tor article incorporation approval change b prospective approval general meeting march board executive aggregate remuneration cov line precede section report principle ere vegv submit prospectively board govern specific remuneration component director separate bind approval period ordinary agms bonus salarie chairman board director member corporate executive committee follow page provide detailed information remu decide remuneration committee take neration pay member board director account revision roche remuneration policy market member corporate executive committee comparison leading pharmaceutical company financial year include comparison remuner management change ation pay previous year remuneration vicechairman board remuneration member board director board member consist fix cash payment set member board director receive discretion remuneration committee fix remuneration cash payment show remuner remuneration committee assist consultancy tower ation member board director table watson track cash payment roche director board activity basic remuneration board market datum director pay lead global director remain unchanged remuner pharmaceutical company major swiss compa ation member board director remain ny footnote unchanged b policy procedure submit total board exception severin schwan members board executive remuneration shareholder approval director award share nonvoting equity annual general meeting security stocksettle stock appreciation right ssar year annual general meeting agm shareholder rsus approve total remuneration decide board direc tor remuneration committee board director william burns receive honoraria amount total corporate executive committee dollar swiss franc serve mem ber board director chugai pharmaceutical co ltd arthur levinson receive payment consult work serve board genentech amount dollar swiss franc httpwwwrochecomaboutrochecorporategovernance list member position committee membership articleofincorporationhtm chairmanship roche annual report remuneration reporta remuneration member board director additional additional c ompensation additional c ompensation additional special special remuneration committee c ompensation remuneration committee c ompensation memberschairs memberschairs chf chf chf chf chf chf f b humer b high total remuneration pay member b high total remuneration pay member board director board director hoffmann p baschera j bell p bulcke w burns ch franz julius levinson oeri schwan high total remuneration pay member corporate executive committee remuneration receive primary function ceo reflect total remuneration corporate executive committee p r voser b weder di mauro remuneration member board director retire b gehrig l j r de vink total exception member presidium vicechairmen board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration serve vicechairman board period january march prorate remuneration period january march b high total remuneration pay member programme psp rsus long enrol board director roche ssar programme chairman franz b humer member board high total remuneration chairman severin schwan executive member board director remuneration consist base salary bonus award receive remuneration primary function ceo chairman board handover executive reflect high total remuneration pay member function ceo annual general meeting march corporate executive committee include total receive additional ssar ne pay corporate executive committee remuneration report roche annual report high total remuneration pay member board director chf chf chf salary bonus cash paymentblocke share proposal ordinary agm total pension fundsmgb roche connect total value share transfer end april calculation value base month average price swiss franc october december consideration reduction value block period year reduce market value detailed calculation remuneration annual report mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include annual expense allowance chf payment tax consulting service chf include employer contribution ahvivalv chf c stocksettle stock appreciation right ssar e board remuneration subject approval december william burns mem annual general meeting ber board director hold ssar position member corporate executive com submission chairman total aggregate bonus mittee hold stocksettle stock appreciation right ssar bind vote annual general meeting show ssar table board director propose award chairman board bonus roche share block period total remuneration pay board director year value swiss franc respect member board director receive financial year submit proposal remuneration totalling swiss franc ordinary annual general meeting agm bind vote swiss franc anticipation enactment switzerland new ordinance excessive compensation list corporation ver loan credit grant member ordnung gegen bermssige vergtungen bei brsenko board director tierten aktiengesellschaften vegv horst teltschik member board chairman board receive additional bonus director receive honoraria amount euro respect financial year payable april swiss franc serve board roche remuneration committee adopt bonus proposal late subsidiary germany euros ie swiss submit proposal shareholder approval franc horst teltschik decide stand ordinary agm reelection board member b submission board total aggregate future additional remuneration pay remuneration bind shareholder vote board director propose ordinary agm approve board remuneration totalling swiss franc period end ordi nary agm ordinary agm ordinary agm rounded sum swiss franc exclude bonus include annual salary swiss franc new chairman board roche annual report remuneration reportin franz b humer chairman board direc remuneration member corporate executive tor receive remuneration swiss franc committee general provision assign authority cash work end march prorate decision corporate executive committee remuneration pay ordinary agm remuneration committee board director include board aggregate future remuneration outline page remuneration report chairman board directors severin schwan executive member board directors franz b humer serve year advisory capacity receive remuneration primary function ceo presidium phase handover reflect high total remuneration pay member mandate intensive reduce corporate executive committee considerably total remuneration set board clude total pay corporate executive director publish roche annual report say committee h remuneration maximum swiss franc total include figure give future total remuneration board director subject shareholder approval pay ordinary gen eral meeting high total remuneration pay severin schwan member corporate executive committee high total remuneration pay member corporate executive committee chf chf chf salary ssar grant value accord trinomial model american option rsus restrict stock unit pension fundsmgb insurance roche connect subtotal bonus cash payment block nonvoting equity securitiesshare psp total value calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market value detailed calculation remuneration annual report number ssar grant value accord trinomial model american option chf trinomial model american option value describe remuneration member corporate executive committee c stocksettle stock appreciation right ssar number rsus grant value chf ne average market price day period prior grant date march rsu calculation value consideration reduction value additional block period year reduce market value mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit share transfer april calculation value base month average price swiss franc october december consideration reduction value block period year reduce market value total estimate value psp award originally target ne award ne total spread relevant period time ie year value calculate yearend price december chf nonvoting equity security ne psp estimate value calculate yearend price december chf non vote equity security ne base number ne originally target ne ne respectively subject change number value ne awardable plan december december respectively spread relevant period time ie year board director vote actual allocation originally target ne december december respectively accord tsr achieve include annual expense allowance chf payment tax consulting service chf exclude employer contribution ahvivalv payment chf remuneration report roche annual report remuneration remain member corporate executive committee base pay chf annual salary annual salary annual salary ayyoubi r diggelmann hippe g keller oday total member corporate executive committee prorate remuneration period april december include chf loss pension right grant employer contractual agreement b bonus severin schwan member corporate remuneration committee board director deter executive committee receive bonus mine corporate executive committee member bonuse cash payment end april severin january base performance schwan receive bonus form roche share agree objective total aggregate bonus block year bonus payment bring forward bind vote annual general end april meeting bonus bonus bonus bonus total total total chf chf chf ayyoubi cash payment block nonvoting equity security total bonus r diggelmann cash payment block nonvoting equity security total bonus hippe cash payment block nonvoting equity security total bonus g keller cash payment block nonvoting equity security total bonus oday cash payment block nonvoting equity security total bonus total member corporate executive committee prorate remuneration period april december roche annual report remuneration reportc stocksettle stock appreciation right ssar time prior maturity call american option com ssar show ssar table pare european option allow exercise introduce roche january place stock maturity date option ssar entitle holder benefit financially increase value roche nonvoting equity security number ssar strike price expiry date ne grant date exercise date grant value ssar show ssar table strike price ssar term multiyear plan number ssar calculate time closing price roche ne grant date ssar issue enter value table vest year grant date vest ssar exercise convert ne seven year grant date unexercised ssar lapse compensation fair value ssar calculate grant date information trinomial model american option refer boyle phelim p lattice framework option pricing trinomial model american options trinomial state variable journal financial quantitative model effective method valuation american analysis volume issue mar wwwrochecom trinomialmodelpdf options consider possibility exercise option strike price table ssar stocksettle stock appreciation right ssar ssar ssar ssar value chf value chf value chf ayyoubi r diggelmann hippe g keller oday total member corporate executive committee restrict stock unit rsus replace ssar value ssar award reduce start begin restrict stock unit balance award form rsus rsus right receive nonvoting equity security year vest period plus value adjustment rsu award allocate individually remuneration equivalent sum dividend pay committee discretion vest recipient vest period attributable number nonvoting equity year result nonvoting equity secu securities individual award grant ritie remain block year introduce new remuneration component partially remuneration report roche annual report restrict stock unit rsus rsus rsus number value chf ayyoubi r diggelmann hippe g keller oday total calculation value number rsus multiply grant value chf ne average market price day period prior grant date march rsu calculation value consideration reduction value additional block period year reduce market value e performance share plan psp security market price dividend yield ie total member corporate executive committee shareholder return tsr calculate chf con member senior management currently individu stant exchange rate reduce effect shortterm mar al worldwide participate performance share plan ket fluctuation security price average psp month october december prior start perfor mance cycle month october decem psp move overlap threeyear performance ber end cycle cycle new cycle beginning year cycle progress psp psp roche security perform well average peer psp psp close set roche tsr increase cycle december target ne award board director elect increase nes award maximum award double original level reserved target previous year psp psp psp number ne accord psp plan start psp psp close award cycle plus value adjustment target ne equivalent sum dividend pay vest period attributable number nonvoting equity securi provision plan number nonvoting tie individual award grant equity security nes reserve partici require roche security perform well pant cycle number security actually award peer set event investment depend extent investment roche security underperform average return deliver roche security share ne outperform average peer company few ne award return investment security issue peer set comparator company comparison base footnote roche annual report remuneration reportperformance share plan psp total estimate award value psp award target ne ne ne number award award award target number target number ne ne psp ne psp psp psp psp psp value chf value chf value chf value chf ayyoubi r diggelmann hippe g keller oday total member corporate executive committee total estimate value psp award originally target ne award spread relevant period time ie year value calculate yearend price december chf nonvoting equity security ne psp estimate value calculate yearend price december chf nonvoting equity security ne base number ne originally target subject change number value ne awardable plan december december respectively spread relevant period time ie year board director vote actual allocation originally target ne december december respectively accord tsr achieve ne reserve plan member f indirect benefit corporate executive committee show table employer contribution social security board director decide scheme pension plan groupwide employee stock actual level ne cash equivalent award cycle purchase plan roche connect respect member close corporate executive committee show indirect financial year respectively aim psp provide benefit table page incentive participant achieve steady value growth roche connect voluntary stock purchase plan offering end psp cycle base employee opportunity buy roche nonvoting equity month move average distribute dividend total security ne equal annual billion swiss franc billion swiss franc salary discount ne purchase plan billion swiss franc billion swiss subject hold period year switzerland franc tsr roche security ne share rank th compare peer set company operate industry accord term plan participant receive originally target ne table detail remuneration report roche annual report indirect benefit pension payment pension payment fund tax fund tax mgb ahviv roche consulting mgb ahviv roche consulting insurance alv connect service insurance alv connect service chf chf chf chf chf chf chf chf ayyoubi r diggelmann hippe g keller oday total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit g remuneration emolument loan executive remuneration subject approval member corporate executive committee additionally annual general meeting receive annual expense allowance swiss franc totalling swiss franc ubmission executive total aggregate bonus bind vote annual general meeting base contractual obligation roche pay indi board director propose award member vidual member corporate executive committee corporate executive committee bonus total children school cost foreign tax obligation relo swiss franc respect financial year cation cost total swiss franc swiss franc submit propose total ordinary annual general meeting agm loan credit grant member bind vote anticipation enactment switzer corporate executive committee land new ordinance excessive compensation list corporation verordnung gegen bermssige ver pension total swiss franc pay gtungen bei brsenkotierten aktiengesellschaften vegv corporate executive committee member b ubmission executive total aggregate maximum regular period notice member remuneration bind shareholder vote corporate executive committee month board director propose ordinary agm changeofcontrol clause employment contract approve remuneration corporate executive committee totalling swiss franc ordinary h total remuneration pay member agm ordinary agm rounded sum swiss corporate executive committee franc exclude bonus period end member corporate executive committee ordinary agm receive remuneration totalling swiss franc swiss franc include ahvivalv compose base pay longterm incentive ssar rsus calculate grant value consid additional remuneration mention ere reduction value block period applica payment pay current member cor ble psp calculate time reservation nonvot porate executive committee ing equity security take account potential double contribution pension benefit roche annual report remuneration report alignment interest manager pensation accord ssar plan rule mis shareholdersholder nonvoting equity security conduct participant include inter alia ssar psp remuneration component intend activity lead disciplinary action align management interest shareholder repeat willful failure perform duty holder nonvoting equity security participat reasonably assign roche ing manager additional incentive achieve continue violation law public regulation value growth form longterm total shareholder return commission crime create value roche investor management benefit gross negligence willful misconduct employment add value create investor manage engage conduct bring disgrace disrepute roche ment penalise receive andor subsidiary violation roche directive guideline relate business conduct clawback addition applicable statutory provision roche long accord regulation psp programme origi term incentive plan include option partially reclaim dis nally target award ne shall lapse tribute compensation result special circumstance compensation notice termination employment clawback give reason redundancy disability retire ment employee voluntarily serve notice termination employment ssar rsus unvested date termination employment lapse immediately guideline security holding compensation board director decide ceo cec member acquire share andor ne equivalent termination employment result miscon annual base salary ceo annual base salary duct ssar rsus grant outstanding respectively end retain holding vest unvested shall lapse immediately com long serve cec type security value ceo share andor nes x annual base salary member corporate executive committee share andor nes x annual base salary security holding note financial statement roche holding ltd directors andr hoffmann andreas oeri member significant shareholder addition founder family closely associate december december respectively belong shareholder group pool voting right member board director person closely asso end group hold share ciate member cec person issue share detailed information group closely associate held share ne show find finance report note roche group con table security holding solidate financial statement relate party remuneration report roche annual report security holding december december close close relative relative security security holding holding share ne number share ne number number number type number number number type number board director f b humer ssar hoffmann ubs longshort certificate link roche bearer share roche nonvoting equity securities valor isin ch expiry date march p baschera j bell p bulcke w burns ssar ssar ch franz julius levinson oeri ubs longshort certificate link roche bearer share roche nonvoting equity securities valor isin ch expiry date march schwan security holding na na na na corporate executive committee p r voser b weder di mauro retire direc tor board b gehrig na na na na l j r de vink na na na na american depository receipts adr rhhby isin total roche annual report remuneration reportsecurity holding december december close close relative relative security security holding holding share ne number share ne number number number type number number number type number corporate executive committee schwan ssar ssar ayyoubi ssar ssar r diggelmann ssarsoption ssarsoption hippe ssar ssar g keller ssar ssar share share oday ssar ssar total share share share hold shareholder group pool voting right list remuneration report roche annual report ssar number ssar hold current member corporate executive committee december total corporate executive committee schwan ayyoubi r diggelmann hippe g keller oday total corporate executive committee member w burn strike price chf market price ne december chf expiry date grant value ssar chf trinomial model american option value accord correspond annual report position option hold option show table issue roche employee stock option option entitle holder purchase roche nonvoting equity security ne term multiyear option plan strike price option show closing price roche ne grant date option show nontradable onethird option subject vest period year onethird vest period year onethird vest period year unvested option lapse compensation employment terminate voluntarily reason retirement vest option exercise limited period time william burn receive additional ssar william burn receive ssar member corporate executive committee roche annual report remuneration report remuneration report roche annual report web research development roche pharmaceutical diagnostic pipeline wwwrochecompipeline personalise healthcare wwwrochecompersonalisedhealthcare group policy positions guideline wwwrochecomresponsibilitysustainabilitypositionspoliciesdownloadshtmguideline clinical trial safety wwwrochecomclinicaltrial wwwrochecommanagingmedicationsafety global standard httpwwwrochecomresearchanddevelopmentwhowearehowweworkclinicaltrialsglobalstandardshtm animal welfare wwwrochecomanimalwelfare manufacturing procurement pharmaceutical supply chain initiative wwwpharmaceuticalsupplychainorg stakeholder engagement wwwrochecomstakeholderengagement supplier code conduct wwwrochecomrochesuppliercodeofconductpdf market product wwwrochecomproduct access healthcare overview wwwrochecomaccesstohealthcare genentech access solution wwwgenentechaccesssolutionscom list patient group support wwwrochecompatientgroup integrity responsible marketing wwwrochecombusinessintegrityandresponsiblemarkete roche policy guideline position wwwrochecompositionspoliciesdownloadshtm responsible business roche group code conduct wwwrochecomcodeofconduct roche supplier code conduct wwwrochecomrochesuppliercodeofconductpdf position policy guideline wwwrochecompositionspoliciesdownloadshtm roche position respect human right wwwrochecomresponsibilityemployeeshumanrightshtm risk management compliance wwwrochecomriskmanagementandcompliance integrity responsible marketing wwwrochecombusinessintegrityandresponsiblemarketing list patient group support wwwrochecompatientgroup roche clinical trial patient safety wwwrochecomclinicaltrial wwwrochecommanagingmedicationsafety counterfeit wwwrochecomcounterfeite patent intellectual property wwwrochecompatent stakeholder engagement wwwrochecomstakeholderengagement roche annual report additional online informationour people employee wwwrochecomemployee global career portal httpcareersrochecom employment policy wwwrochecomemploymentpolicypdf group policy position guideline wwwrochecompositionspoliciesdownloadshtm commitment wwwrochecomcommitment health safety wwwrochecomenvironment community involvement roche commission httpwwwrochecomrochecommissionshtm roche continent httpwwwrochecontinentsnetrochecontinentshtml roche children walk httpwwwrochecomchildrenswalkhtm safety security health environment environmental protection wwwrochecomenvironment policy guideline position paper httpwwwrochecomresponsibilityenvironmentourshepoliciesguidelinesandpositionpapershtm goal performance httpwwwrochecomresponsibilityenvironmentourshegoalsandperformancehtm corporate governance remuneration report httpwwwrochecomaboutrochecorporategovernancehtm httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm httpwwwrochecomaboutrochemanagementboardofdirectorshtm httpwwwrochecomaboutrochemanagementexecutivecommitteehtm httpwwwrochecomaboutrochecorporategovernanceannualgeneralmeetingshtm httpwwwrochecomaboutrochecorporategovernancecommitteeshtm httpwwwrochecomcorporateresponsibilitybusinessethicsriskmanagementandcompliancehtm httpwwwrochecomcorporateresponsibilityenvironmenthtm httpwwwrochecomcorporateresponsibilityhtm httpwwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm httpwwwrochecommediahtm httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernancecodeofconducthtm wwwrochecomtrinomialmodelpdf additional online information roche annual report independent assurance report roche corporate responsibility report corporate governance sustainability committee define guideline people donation roche hold ag basel roche sponsorship key figure internally gather collate aggregate engage perform assurance procedure principle summarise page report provide limited assurance aspect corporate define scope reporting responsibility cr report roche include annual report report accuracy completeness cr indicator subject inherent limitation give nature method scope subject matter determine calculate estimate datum limited assurance engagement focus follow surance report read connection datum information disclose cr report roche roche internal guideline definition procedure consolidate subsidiary year end decem report cr performance ber management reporting process respect responsibility methodology cr report material aspect preparation roche corporate governance sustainability commit safety security health environmental protection tee responsible subject matter criterion people donation sponsorship key figure selection preparation presentation relate control environment relation datum aggre select information accordance criterion gation key figure responsibility form independent opinion base key figure include scope greenhouse gas limited assurance procedure come emission business travel table graphs attention indicate identify cr information page people key figure disclose page select contain report state mate report rial respect accordance report criterion consolidate data information roche group level relation donation sponsorship breakdown plan perform procedure accordance disclose international standard assurance engagement isae assurance engagement audits criteria review historical financial information standard management reporting process respect cr require comply ethical requirement plan report key figure assess internal perform assurance engagement obtain limited assur policy procedure set forth follow ance identify cr information roche group internal cr report guideline base responsible care health safety environmental subject matter provide limited assurance protection report guideline publish european nature timing extent procedure gather suf chemical industry council cefic sustainability ficient appropriate evidence deliberately limited relative reporting guideline g publish global reasonable assurance engagement reporting initiative gri roche group internal corporate reporting manual ver comply independence ethical sion sustainability report economic performance requirement code ethic professional accoun datum tant issue international ethic standard board roche annual report independent assurance report roche corporate responsibility reportingaccountant found fundamental principle carry work datum report prior integrity objectivity professional competence care reporting period perform work respect confidentiality professional behaviour projection target conduct work datum outline subject matter define perform task service roche conflict independence believe evidence obtain sufficient responsible preparation report appropriate provide basis assurance conclu qualify independent define code sion ethic applicable legal regulatory requirement limited assurance conclusion summary work perform base work describe report assurance procedure include fol come attention cause believe lowing work roche group internal cr report guideline base evaluation application gri g sustainability report guideline roche group guideline cefic guideline apply material respect review application roche group internal cor come attention cause believe porate cr donation sponsorship guideline internal reporting process collect aggregate site visit management inquiry people donation sponsorship datum visit select site roche pharmaceutical function design provide appropriate basis diagnostic division argentina belgium nether disclosure material respect land south korea taiwan selection base come attention cause believe quantitative qualitative criterion cr information mention subject matter interview personnel responsible internal cr reporting disclose cr report roche annual data collection site visit roche report state material respect accor group level determine understand application dance reporting criterion roche internal cr guideline assessment key figure perform test sample basis evidence support zurich january select people donation sponsorship key fig ure roche accident rate energy consumption green pricewaterhousecoopers ag house gas emission relate energy consumption halo genate hydrocarbon waste headcountfte datum staff statistic labor practice information contribution philanthropic organization patient organisation health institution public policy body concern completeness christophe bourgoin stephan hirschi accuracy adequacy consistency inspection documentation analysis relevant policy principle inspect relevant documentation sample basis clude roche group cr policies management report structure documentation inspect principle roche materiality process provide definition development adherence gris social environmental reporting requirement assessment process data consolidation review management ofand cr reporting process people donation sponsorship key figure assess consolidation process datum roche group level independent assurance report roche corporate responsibility report roche annual report publish cautionary statement forwardlooke f hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooking statement tel forwardlooke statement identify word believe expect anticipate project intend seek fax estimate future similar expression discussion thing strategy goal plan intention factor medium office cause actual result differ materially future group communication reflect forwardlooke statement contain annual basel switzerland report price product nitiative com tel petitor legislative regulatory development economic fax condition delay inability obtain regulatory approval bring product market fluctuation currency exchange rate g eneral financial market condition uncertaintie investor relation discovery development marketing new product new use basel switzerland exist product include limitation negative result tel clini cal trial research project unexpected effect pipeline fax market product increase government pricing pressure interruption production loss inability obtain ade website quate protection intellectual property right litigation loss wwwrochecom key executive employee adverse publicity news coverage corporate sustainability committee statement earning share growth profit tel forecast interpret mean roche earning email corporatesustainabilityrochecom earning share subsequent period nece sarily match exceed h istorical publish earning earning order publication share roche tel fax trademark mention enjoy legal protection email baselwebmasterrochecom link thirdparty page provide convenience express opinion content thirdparty page annual general meeting expressly disclaim liability thirdparty information march use roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue f hoffmannla roche ltd basel group communicationsf hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom e roche annual report x key figure group sale operate free cash flow millions chf cer millions chf cer core operating profit ifrs net income millions chf cer millions chf cer core earning share dividend annual report xxx x chf cer chf total shareholder return value chf invest period end dec feb apr jun aug oct dec roche gs price roche b price peer set index sustainable company patient clinical trial patient treat employee global leader innovation biotech oncology vitro diagnostic hospital market cer constant exchange rate average fullyear price translate constant chf exchange rate ifrs international financial reporting standard usd eur jpy gbp propose board director roche selling product fulltime equivalent rochearugengindd rochearfront coverengindd rochearkey figureseng